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     Herpes simplex virus type 1 (HSV-1) replicates in the nucleus and buds 
through the nuclear membrane to access the cytosol and complete the 
maturation process. The HSV-1 protein pUL31, along with its binding partner, 
pUL34, has been previously shown to be required for nucleocapsids to 
successfully bud through the nuclear membrane. pUL31 is also required for 
efficient viral DNA synthesis and packaging. After the HSV-1 exits the nucleus, 
the capsid acquires several accessory proteins (tegument) and finally a 
mature envelope by budding into vesicles of the trans-Golgi network (TGN). 
These virion-laden vesicles traffic toward the cell periphery and through 
cortical actin until ultimately the virion is secreted upon fusion of the TGN 
vesicle with the plasma membrane.  
     The data presented here reveals new roles for pUL31, as cells infected with 
a UL31-null virus were delayed for viral gene expression as well as activation 
of NFκB and c-Jun N-terminal kinase (JNK) in multiple cell lines. At least one 
representative from each kinetic class of viral genes was examined at various 
times post infection. The protein expression defects were not caused by a 
failure to enter cells, was not rescued by ICP27 expressed in trans and 
correlated with NFκB activation. The data shows that these defects were not 
   
 
observed in the absence of the pUL31 binding partner, pUL34, and that while 
most pUL31 is expressed at late times post infection, low levels are detectable 
as early as 2 hours post infection. 
     Data presented in this work also demonstrates a role for the actin motor 
myosin Va in the secretion of HSV-1 virions. Expression of two isoforms of 
dominant negative myosin Va (DN-myoVa) decreased virion secretion by 50-
75% as well as significantly decreased surface expression of viral 
glycoproteins B, M and D. DN-myoVa colocalized with TGN markers and the 
conformation of native myosin Va in infected cells was altered by 4 hours post 
infection. These data suggest that myosin Va is involved in the egress of 
virion-laden TGN vesicles as they transit through cortical actin toward the 
plasma membrane. 
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CHAPTER I 
Introduction 
 
Overview of Herpesviridae  
 The family Herpesviridae consists of more than 120 different viruses and can 
be subdivided into three subfamilies: alpha-, beta- and gammaherpesvirinae 
(132). The primary difference between the viruses comprising each subfamily 
is the viral replication kinetics, with the alphaherpesviruses replicating and 
spreading the fastest (less than 24 hours). The best studied alphaherpesvirus, 
herpes simplex virus type 1 (HSV-1), is the model virus of this family and is the 
subject of many review articles (85,96-98,121,146). 
 The hallmark of herpesvirus infections is the ability to establish latency. For 
the neurotropic alphaherpesviruses, latency is established in sensory neurons 
where the linear DNA genome circularizes and exists as a stable episome for 
the lifetime of the host. Occasionally, environmental stresses such as UV 
exposure will cause the quiescent genomes to reactivate and produce 
infectious virions. During active infections, HSV-1 causes cold sores (lesions 
on or near the mouth), and more rarely, blindness and encephalitis. 
 
Overview of Virion Structure  
     Herpesviruses are enveloped and contain a double stranded, linear DNA 
genome of 152kb encoding more than 80 genes. The genome consists of two 
covalently linked segments, unique long (UL) and unique short (US) and is 
encased within an icosohedral capsid shell (7). The two genomic segments 
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are flanked by inverted repeats, designated ab and b’a’ bordering the UL 
segment and a’c’ and ca flanking the US segment (figure 1.1) (7). Genes 
encoded within the viral genome are transcribed in three sequentially 
regulated phases: α, β and γ. These three classes of genes mostly encode 
transcription regulators, DNA replication machinery and structural (capsid) 
components, respecitively. The virion is approximately 225 nm in diameter 
(51). Between the capsid and envelope is a complex matrix of many viral and 
host proteins (tegument) (83). The capsid is non-centered, with one side of the 
capsid close to the envelope and the other separated by about 35 nm of 
tegument (51). Embedded within the envelope are virally-encoded 
glycoproteins which facilitate both entry into the host cell and egress from the 
nucleus. These features are described in detail below and pictured in figure 
1.1. 
 
HSV-1 Entry 
     Entry of HSV-1 virions requires the attachment of the virion to the host 
through the interaction of a viral glycoprotein(s) with host surface receptor(s). 
Although HSV-1 has at least 12 envelope proteins (83), only four are required 
for entry: glycoprotein D (gD), gB, and the heterodimer gH and gL (gH/gL) 
(121). A receptor for gD is required for HSV-1 to attach and enter a cell, and 
attachment is enhanced by gB and the non-essential gC binding to heparin 
sulfate (HS) proteoglycans. Other than HS, known gB receptors include paired 
Ig-like type 2 receptor α (PILRα), and surprisingly, the heavy chain of non-
muscle myosin IIA (NMIIA) (4,136). NMIIA is a cytoplasmic actin binding 
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Figure 1.1 Structure of HSV-1 virion and genome. (A) Structure of an HSV-
1 virion. Pictured are viral glycoproteins, the host-derived envelope, tegument, 
capsid and packaged genome. (B) Structure of the linear DNA genome of 
HSV-1. Pictured is a map of the unique long (UL) and unique short (US) 
regions as well as the long and short inverted repeats (RL and RS, 
respectively). 
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protein that can bundle and contract parallel actin filaments (22,162). How this 
cytoplasmic protein is expressed on the cell surface and acts as a biologically 
relevant receptor for HSV-1 attachment remains to be determined. 
     Although gB and/or gC can enhance HSV-1 entry by binding the cell 
surface, only binding by gD is absolutely required for entry. The three known 
classes of gD receptors are (i) HVEM (herpesvirus entry mediator), a member 
of the tumor necrosis factor (TNF) receptor family; (ii) nectin-1 and nectin-2, 
members of the immunoglobulin (Ig) superfamily; and (iii) 3-O sulfated heparin 
sulfate (3-O-HS). After attachment by gD, the virion fuses its envelope with the 
host membrane to access the cytosplasm. Fusion is accomplished by the 
coordinated actions of the central fusion machinery: gB and gH/gL (121). 
Although gD is required for entry, is not believed to be part of the fusion 
machinery because the structure of this glycoprotein does not resemble a 
fusion protein. Fusion of the virion envelope with the host membrane can 
occur at the plasma membrane surface or within an endocytosed vesicle and 
varies between cell lines (19,100,106,107,169). This is described with greater 
detail in chapter II. 
     After the HSV-1 capsid has accessed the cytoplasm, many of the outer 
tegument proteins disperse away from the capsid and prime the cell for 
infection. The capsid maintains association with some (inner) tegument, such 
as the gene products for UL36 and UL37 (pUL36 and pUL37, respectively), and 
utilizes microtubules and the microtubule motor dynein to traffic to a nuclear 
pore (32,144). It is unclear which inner tegument protein(s) and/or capsid 
proteins are interacting with the dynein motor and if any other cellular factors 
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are involved. pUL36 and/or pUL37 are potential candidates for dynein 
interaction, as both are required for entry and have been shown to remain 
associated with incoming capsids (7). After trafficking along the microtubules 
and reaching the nucleus, the capsid docks at an unknown component of the 
nuclear pore complex (NPC) and releases the genome into the interior of the 
nucleus (6,154). 
     As the capsid delivers the genome to the nucleoplasm, outer tegument 
proteins work to establish an environment conducive to HSV-1 infection. For 
example, pUL41 [virion host shut off protein (vhs)], destabilizes the preexisting 
mRNAs within the host cell (42,137,151). This is beneficial for two reasons: (i) 
by removing the bulk of preexisting host mRNA the cellular machineries will 
favor translation of newly transcribed viral mRNA; and (ii) by destabilizing the 
half-lives of mRNA, vhs increases the efficiency of transitioning from one 
phase of viral transcription to the next. Other examples of tegument 
influencing early cellular events include pUL37, which has been shown to 
activate NFκB (nuclear factor κB) signaling pathways through an interaction 
with TNF receptor-associated factor 6 (TRAF6) (82); and pUL48 [also known 
as α-transinducing factor (α-TIF), VP16 or vmw65] which associates with host 
cell factor (HCF-1) and Oct-1 in the nucleus and initiates viral transcription 
(47,148,175). 
 
Transcription Kinetics of HSV-1 
     Herpesviruses transcribe their genes in a temporally regulated cascade 
comprised of three basic classes: immediate early (α), early (β), and late (γ). 
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The γ genes can be further subdivided into γ1 and γ2 (leaky late and true late, 
respectively). The distinction between γ1 and γ2 gene expression is separated 
by the requirement for viral DNA (vDNA) replication. If vDNA replication is 
inhibited, γ1 gene expression is diminished and γ2 gene expression is 
precluded. The kinetic class of HSV-1 genes is largely defined by the 
corresponding promoter (see figure 1.2) and the temporal cascade of gene 
expression is mediated in part by viral proteins acting as transactivators. 
    One very important activator of viral genes is α-TIF, which is brought in with 
the viral tegument. The N-terminal half of α-TIF associates with the host 
factors HCF-1 and Oct-1 and the complex binds to consensus TAATGARAT 
(R is a purine residue) DNA sequences within α gene promoters 
(108,115,116,148,164,175). This protein-DNA interaction occurs at single or 
multiple sites upstream of individual genes and initiates α gene transcription. 
As the α genes are made, new regulators act to influence viral gene 
expression. If translation is blocked at the start of infection, only α gene 
transcripts are produced from the viral genome.      
     Promoters for α genes contain TATA and CAAT boxes, similar to other 
polymerase II promoters in cellular genes. Unique to α promoters are the α-
TIF interacting regions. These immediate early promoters have a 
TAATGARAT DNA binding site for α-TIF complexed with host proteins to 
initiate α gene expression. Immediate early promoters also have a variable 
number of repeated SP1 binding sites upstream of the TATA box. Some α 
promoters also have an ICP4 binding site. The α gene products are mostly  
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Figure 1.2 Examples of HSV-1 immediate early, early and late promoters. 
Schematic representation of generic examples of HSV-1 promoters of each 
kinetic class and the cis-acting regulatory segments is shown above. The 
immediate early promoters have a TAATGARAT DNA binding site for α-TIF 
complexed with host proteins to initiate α gene expression. These promoters 
also have a variable number of repeated SP1 binding sites upstream of the 
TATA box and some have an ICP4 binding site. β promoters contain 
eukaryotic elements upstream of the TATA box, but no known downstream 
elements. These promoters resemble typical polymerase II promoters existing 
in host cells. γ promoters contain cis-acting elements downstream of the TATA 
box, including an initiator element (INR) at the transcription start site and some 
γ promoters also have downstream activation sites.
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transcription regulators, including ICP0, ICP4 and ICP27. Among other roles, 
ICP0 augments expression of α, β and γ genes. ICP27 augments γ gene 
expression and interacts with RNA polymerase II to help initiate transcription 
(176) by recruiting the polymerase to viral replication sites within the nucleus 
(26). Once these viral transcripts are produced, ICP27 binds viral mRNA 
(23,135) and helps mediate its export to the cytoplasm (75,135,145). ICP27 
has also been shown to be required for the activation of NFκB during HSV-1 
infection (57). ICP4 augments β and γ gene expression and also down 
regulates mRNA expression of some α genes, including itself. 
     ICP4 is one of the best studied HSV-1 genes. It is encoded by RS1 and 
present in two copies within the viral genome. Functional ICP4 protein is 
required for the progression of both β and γ gene expression (7). The 
mechanism of ICP4-mediated repression involves an ICP4 binding site near 
the transcription start site (figure 1.2) but does not act through steric 
interference of transcription. Instead, ICP4 is believed to associate with other 
transcriptional regulatory factors such as the TATA-binding protein (TBP) and 
the transcription factor TFIIB (53,77). The mechanism(s) of ICP4-mediated 
activation of HSV-1 genes is not fully understood, but the transactivation by 
ICP4 appears to involve interaction of ICP4 with TFIID (52) through an 
interaction with the TBP-associated factor (TAF) 250 (13). 
     β genes encode proteins important for vDNA replication. Some of the 
essential β gene products include pUL30 (DNA polymerase), pUL29 (ICP8) 
and pUL42 (DNA binding proteins), and pUL5 (helicase/primase complex). 
Without these and other β gene products, vDNA replication cannot proceed 
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and consequently γ gene transcription is blocked. 
     Thymidine kinase (TK or UL23) is another example of a β gene product and 
was one of the first viral genes to be studied in detail. TK gene expression 
requires ICP4 for expression, but mutational experiments on the promoter 
controlling expression of TK revealed the perplexing finding that the cis-acting 
elements were the same as those required for eukaryotic genes. These 
elements include a TATA box, two SP1 binding sites and a CAAT element 
(figure 1.2) and no other elements were found to be necessary (21,34,89-92). 
It is still unclear how β gene expression is regulated and why TK mRNA 
transcription requires ICP4 when all of the cis-acting elements required for 
expression by host machinery appear to be present. 
     Upon high levels of vDNA replication, the γ genes are transcribed and the 
cell is committed to producing virions until eventually the cell is destroyed. The 
late genes encode mostly structural proteins and are produced in two 
subclasses: γ1 (leaky late) and γ2 (true late). Inhibition of vDNA synthesis will 
decrease the efficiency of γ1 gene expression, preclude γ2 gene expression 
and prolong the expression of early genes. Thus, the transition from early to 
late gene expression is linked with vDNA replication and requires ICP4-
mediated activation at the TATA box within γ promoters. 
     Late gene promoters have a TATA box and downstream cis-acting 
elements, but these promoters do not have other cis-acting elements 
upstream of the TATA box (figure 1.2) (54,66,73,87). Examples of γ1 gene 
products include ICP34.5 (a neurovirulence gene required for 
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dephosphorylation of eIF2-α and protein synthesis) and VP5 (UL19, the major 
capsid protein). Examples of γ2 gene products include gC and VP16 (UL48, a 
tegument protein) (7). 
     During the transition from β to γ gene expression, the viral genome forms 
into specialized domains known as viral replication compartments (RCs). Late 
gene transcription, vDNA replication and encapsidation take place within these 
domains. As the RCs develop, host chromatin is marginalized against the 
inner nuclear membrane, nuclear lamina and RCs. Eventually the host 
chromatin becomes fragmented as the RCs mature and extend to the nuclear 
periphery in a process dependent upon pUL34 and pUL31 (142). These 
nuclear alterations and reorganization of vDNA may be a key process in viral 
gene regulation. Further studies are required to elucidate this possibility. 
 
Alterations in Nuclear Architecture During HSV-1 Infection 
     During HSV-1 infection, the host nucleus undergoes many changes to 
accommodate the replication of vDNA and the assembly and egress of 
nascent nucleocapsids. As the vDNA replicates, replication compartments 
(RCs) form and marginalize host chromatin to the nuclear rim. As the RCs 
mature, they push through the marginalized chromatin to the nuclear periphery 
(102,142). The nucleus has been shown to expand in size two-fold in infected 
HeLa cells at about 8 hours post infection (102). HSV-1 induced nuclear 
expansion was shown to require pUL31 and pUL34 and was precluded by 
treatment with the actin depolymerizing drug cytochalasin D (143). The 
nuclear lamina is also modified by pUL31, pUL34 and US3, which may be 
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important for egressing nucleocapsids to access the inner nuclear membrane 
and bud out of the nucleus (described below) (122-124,128,131,163). 
 
Nucleocapsid Assembly 
     HSV-1 capsids are icosahedral (T=16) with 162 capsomers and 12 
vertices. The capsid is made up of several viral proteins, including pUL19 
(VP5, the major capsid protein), pUL18 and pUL38 (triplex proteins), UL6 (the 
portal) and pUL35 (VP26, a non-essential protein that decorates the hexon 
tips). Assembly of these proteins occurs autocatalytically in the nucleoplasm, 
and the capsid builds around a scaffold protein (pUL26.5).  
     Encapsidation occurs by driving unit length genomic material from vDNA 
concatamers through the portal by the terminase complex (pUL15, pUL28 and 
pUL33) and is ATP-dependent. Packaging of vDNA is concomitant with 
proteolytical cleavage of the scaffold by pUL26 (the protease). Cleavage of the 
scaffolding is followed by its expulsion from within the nucelocapsid. A fully 
packaged capsid with the scaffolding completely extruded is referred to as a 
“C capsid.” DNA-free capsids which have lost the scaffold are referred to as “A 
capsids” and capsids that contain scaffold but failed to package vDNA are “B 
capsids.” 
     Also required for vDNA packaging and retention of the packaged genome 
within the capsid are pUL17 (134,152) and pUL25 (20,93,149), respectively. 
These proteins are believed to form the C capsid-specific complex (CCSC) 
located on top of the triplexes of C capsids as a heterodimer (155,156), and 
presence of the triplex protein UL18 (VP23) is required for pUL17 to efficiently 
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coimmunoprecipitate with pUL25 (138). The CCSC is proposed to engage the 
envelopment machinery at the inner nuclear membrane (see figure 1.3) 
(70,156). 
 
Nuclear Egress of HSV-1 
     Nucleocapsids engage in ATP-, actin- and possibly myosin-dependent 
movement within the nucleus (see chapter II). In order for these capsids to exit 
the nucleus, they must engage the inner nuclear membrane (INM) and bud 
into the perinuclear space, acquiring a primary envelope. This envelope is lost 
as the virion fuses with the outer nuclear membrane (ONM), at which point the 
capsid has accessed the cytoplasm and can continue the maturation process. 
Two viral proteins are essential for successful nuclear budding: pUL34 and 
pUL31 (figure 1.3). pUL34 is a type II membrane protein that localizes to the 
INM and binds the nuclear phosphoprotein pUL31.  
     The pUL34/pUL31 complex is required for egress of capsids from the 
nucleus and the presence of both proteins is required for their proper 
localization (123,124,128). In the absence of pUL31, pUL34 is dispersed 
throughout the INM and endoplasmic reticulum. In the absence of pUL34, 
pUL31 is dispersed within the nucleoplasm and does not associate with the 
INM. pUL31 has also been shown to be important for vDNA packaging (15), 
and efficient activation of NFκB and viral gene expression (chapters IV and V). 
pUL34, pUL31 and the viral kinase encoded by US3 are also required for 
modification of the nuclear lamina.   
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Figure 1.3 HSV-1 budding into the inner nuclear membrane [reprinted 
from reference (70)]. Association of an HSV-1 nucleocapsid with the 
UL31/UL34 complex at the inner nuclear membrane and subsequent budding 
into the perinuclear space. 
 14 
 
      The nuclear lamina is a proteinaceous layer beneath the INM composed of 
integral membrane proteins (e.g. lamin-associated protein 2 and lamin B 
receptor) and a meshwork of intermediate filaments (1,49,172). The 
membrane proteins interact with lamins A, B and C, which are intermediate 
filaments that polymerize in a head-to-tail fashion forming a network lining the 
INM. Lamin C is a splice variant of lamin A. This network of lamins is a barrier 
between egressing nucleocapsids and the INM. HSV-1 induced alterations of 
the lamina are therefore proposed to be required for capsids to gain access to 
the INM and the pUL34/pUL31 complex. 
     Both pUL34 and pUL31 are able to bind directly to lamins, and transient 
expression of pUL34, pUL31 or pUS3 leads to alterations in the nuclear lamina 
(8,103,122). Over expression of pUL34 leads to a partial redistribution of lamin 
A/C into the cytoplasm, while over expression of pUL31 redirects lamin A/C 
into nucleoplasmic aggregates. Over expression of the US3 kinase causes 
disruption of the nuclear lamina (8). The pUL34/pUL31 complex can also 
recruit other factors to the nuclear lamina, including the cellular protein kinase 
C (PKC), which is enriched on the nuclear periphery and phosphorylates 
lamins during infection (111). pUS3 hyperphosphoryates the lamin-interacting 
nuclear membrane protein emerin in a pUL34-dependent manner, which 
modifies emerin’s localization (79). Thus, both viral and cellular factors play a 
role in lamina modifications and nucleocapsid budding at the INM. 
     In addition to modifications of nuclear lamina, viral glycoproteins are also 
required for successful nuclear egress of HSV-1. Deletion of both gB and gH 
results in an accumulation of virions in the perinuclear space (39,98). 
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However, only minor defects were observed with single deletions of either gB 
or gH (39). The apparent redundancy between gB and gH (presumably 
complexed with gL) for fusion with the ONM is notably distinct from entry 
requirements, where gB and gH/gL must be present for fusion to occur at the 
plasma membrane (121). 
 
Cytoplasmic Maturation of HSV-1 
     Once the capsid has transversed the nuclear membranes it must 
accumulate the full complement of tegument proteins and traffic to the trans-
Golgi network (TGN), where it will undergo secondary envelopment (see figure 
1.4 for an illustrative summary of HSV-1 egress). TGN-derived vesicles both 
provide virions with the membrane for their secondary (“mature”) envelope and 
act as the vehicle for delivery to the plasma membrane for secretion.  
     After fusion of the primary envelope with the ONM, the released capsids 
appear to lack tegument by electron microscopy, but immunolabeling 
experiments have indicated that they are associated with pUS3, pUL36 and 
pUL37 (45). The large, multifunctional tegument protein pUL36 has been 
shown to bind the capsid (16,177) and the phosphoprotein pUL37 (46,74).  
     Other tegument proteins, including pUL11 and pUL49, assemble at TGN 
vesicles awaiting secondary envelopment with cytosolic capsids. Deletion of 
gE and gD precludes secondary envelopment in HSV-1 infections, and large 
numbers of tegumented capsids accumulate in the cytoplasm (38). pUL49 has 
been proposed to bind the carboxy-terminal domain of gD (17). The complex 
protein-protein interactions comprising the entire complement of HSV-1  
 16 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Nuclear and cytoplasmic egress of HSV-1 [reprinted from 
reference (70)] Nucleocapsid budding at inner nuclear membrane and 
egressing through the cytoplasm, budding into the TGN and leaving the host 
cell. 
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tegument have yet to be fully elucidated.    
  In the absence of either inner tegument protein pUL36 or pUL37, virion 
formation is blocked (30,31) and it has been shown that inner tegument 
proteins promote HSV-1 capsid movement along microtubules (84,170). 
Similar to entry (above), pUL36 and pUL37 may be important for interactions of 
trafficking capsids with microtubules. Entering and egressing capsids must 
recruit the appropriate motor: the minus-end directed microtubule motor 
dynein for entry and the plus-end directed motor kinesin for egress. It is 
unclear how the appropriate motors are recruited to the capsid, but differences 
in inner tegument composition may be key to this distinction. No direct 
evidence of tegument proteins pUL36 and/or pUL37 interacting with a cellular 
motor protein has been presented (85). 
 
Secondary Envelopment and Secretion of HSV-1 
     Egressing capsids would be expected to acquire their secondary envelope 
at sites of glycoprotein enrichment in cellular organelles. Although several 
putative sites have been postulated including the Golgi, the endoplasmic 
reticulum-Golgi intermediate compartment (ERGIC) and endosomes, the 
strongest evidence suggests that TGN-derived vesicles are the major site of 
secondary envelopment (85,96,98). These vesicles have been shown to 
accumulate viral glycoproteins even in the absence of capsid egress; and 
GFP-labeled capsids were observed to accumulate at the TGN under 
conditions that slowed intracellular transport (158). 
     Although microtubules have been shown to be important for HSV-1 egress, 
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intracellular transport of cargo often requires multiple motors and 
microfilaments. Switching between microtubule and actin motors is not 
unexpected, and very little is known about how the virion-laden TGN vesicles 
traffic to and fuse with the plasma membrane to release HSV-1 (85,96,98). 
Another consideration is the cortical actin lining the plasma membrane. Similar 
to the nuclear lamina (described above), the meshwork of actin filaments lining 
the plasma membrane is a potential barrier to egressing HSV-1 that must be 
overcome for successful secretion. 
     Studies of secretion of other vesicles, such as melanosomes and secretory 
granules, has lead to the discovery for a role for myosin Va in vesicle transport 
through the cortical actin (130,173,174). In these systems, microtubule motors 
(e.g. kinesin) are utilized to traffic to the cortical actin at which point there is a 
“hand off” of kinesin-microtubule based locomotion to myosin-actin based 
locomotion. Experiments observing the trafficking events of melanosomes 
demonstrated a role for myosin Va in the secretion of vesicular cargo 
(173,174). 
     Myosin Va is an unconventional actin motor that consists of two heavy 
chains which dimerize to form duplicate N-terminal head domains and binds 
cargo at two C-terminal globular tail domains (GTDs). This actin motor moves 
cargo along filamentous actin (F-actin) through a series of processive “hand-
over-hand” steps toward the plus end of F-actin (157,159). A dominant 
negative myosin Va construct expressed in melanocytes resulted in 
melanosomes trafficking toward the cell periphery (kinesin-mediated 
movement) and then back toward the center of the cell (dynein-mediated 
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movement). In these cells, the melanosomes accumulated at the center of the 
cell and failed to be secreted (174). Differently, in control cells these vesicles 
were observed to traffic toward and accumulate at the cell periphery (174). 
This was described as a “capture model” where myosin Va was necessary for 
the vesicular cargo to be locally secured within the cortical actin as it 
continued toward the plasma membrane for secretion.  
     Another actin motor, non-muscle myosin IIA (NMIIA), appears be involved 
in HSV-1 egress, as treatment of cells with the putative myosin II inhibitor 
BDM (2,3-butanedione monoxime) resulted in decreased secretion of HSV-1 
infectivity 20- to 50-fold (161). Roles for myosin motors in HSV-1 infections is 
discussed further in chapter II and data supporting a role for myosin Va in 
HSV-1 secretion is presented in chapter III. Conclusions and future studies for 
the work presented in this report are presented in chapter VI. 
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CHAPTER II 
 
Actin in Herpesvirus Infection* 
 
Kari L. Roberts and Joel D. Baines, Department of Microbiology and 
Immunology, Cornell University, Ithaca, NY 14853. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted from Roberts, KL, and J.D. Baines. (2011). Actin in Herpesvirus 
Infection. Viruses, 3:336-346. Copyright © 2011, MDPI. 
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Abstract 
     Actin is important for a variety of cellular processes, including uptake of 
extracellular material and intracellular transport. Several emerging lines of 
evidence indicate that herpesviruses exploit actin and actin-associated myosin 
motors for viral entry, intranuclear transport of capsids, and virion egress. The 
goal of this review is to explore these processes and to highlight potential 
future directions for this area of research. 
 
Overview of Actin-Related Cytoskeletal Components 
     Actin is a highly dynamic protein critical for a wide variety of important 
cellular processes including cell division, adherence, migration, uptake of 
extracellular material, and intracellular transport of vesicles and other cargo. 
There are two basic forms of actin: monomeric or globular actin (G-actin) and 
filamentous actin (F-actin). Formation of F-actin begins by a nucleation event 
from proteinacious complexes such as actin-related protein 2/3 (Arp2/3) (11). 
G-actin subunits assemble in a polarized fashion, forming an actin filament 
with distinctive ends. The plus or “barbed” end of a growing actin filament 
rapidly elongates while the minus or “pointed” end remains relatively static. 
This process is reversible causing actin filaments to rapidly depolymerize as 
subunits dissociate from the plus end. F-actin can also associate with other 
actin filaments to form more complex structures such as actin arrays or 
networks. 
     Three fundamental examples of actin networks are stress fibers, filopodia 
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and lamellipodia (figure 2.1). Actin stress fibers are short, contractile bundles 
of F-actin with alternating polarity. The filaments are held together through 
interactions with the dimeric bundling protein α-actinin and the motor protein 
myosin II, which enables contraction. These fibers are essential for 
maintaining cell attachment to the substratum and implementing changes in 
morphology. Filopodia contain stiff, tightly bound parallel actin bundles that 
polymerize toward the plasma membrane forming a thin, spike-like protrusion. 
These structures may act as probes or sensors of the extracellular 
environment and contain receptors for signaling as well as integrins and 
cadherins (cell adhesion molecules). Lamellipodia are highly branched 
networks of actin filaments, with the highest branching frequency occurring 
nearest the plasma membrane. This “dendritic” sheet-like array of F-actin 
comprises the leading edge of migrating cells and membrane ruffles. 
Generation of these actin structures requires the activity of Rho GTPases. 
These proteins are analogous to molecular switches, existing in either an 
active (GTP-bound) or inactive (GDP-bound) form. The GTPases associate 
with downstream effector proteins in signal transduction pathways (36,55). 
The three most extensively characterized mammalian Rho GTPases, and 
those known to be involved in herpesvirus infections, are RhoA, Rac1 and 
Cdc42. RhoA is associated with the generation of actin stress fibers, Cdc42 
with filopodia, and Rac1 with lamellipodia and ruffling.  
     Rho GTPases have been shown to be important for phagocytosis (55), a 
form of endocytosis involving the internalization of large particles at the cell 
surface,  and known to be used by incoming herpesviruses (explained below).  
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Figure 2.1 Examples of actin networks. Filopodium, stress fiber, and 
lamellipodium structures are featured showing actin polarities.
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Initiation of phagocytosis involves receptor-mediated rearrangement of cortical 
actin localized near the position of the stimulating particle. During Fc receptor 
(FcR)-mediated phagocytosis F-actin accumulates beneath a pedestal-like 
formation and the particle is engulfed by extending pseudopodia that wrap 
around the particle and subsequently fuse (18). In FcR-mediated phagocytosis 
in rat basophil leukemia mast cells, expression of dominant-negative Cdc42 
results in the formation of pedestal-like structures beneath the particles but 
pseudopodia do not form, as observed by scanning electron microscopy 
(SEM) (86). Expression of dominant-negative Rac1 results in particles 
enclosed within pseudopodia that do not fuse (86). While FcR-mediated 
phagocytosis is known to require Cdc42 and Rac1, receptors for complement 
(CR)-mediated phagocytosis induce RhoA-dependent recruitment of Arp 2/3 to 
F-actin rich foci at the site of particle attachment. Although Arp 2/3 is involved 
in both types of phagocytosis, there are no pseudopod extensions in CR-
mediated phagocytosis. Instead, the particle seems to sink into the cell and 
Cdc42 and Rac1 are dispensable for particle uptake, unlike the case of FcR-
mediated phagocytosis.  
     Since actin is crucial to many cellular processes, including uptake and 
short-range intracellular transport (such as the movement of melanosomes 
towards the plasma membrane), it is perhaps not surprising that herpesviruses 
utilize host actin during infection. 
 
 Overview of Herpesvirus Replication 
     The family Herpesviridae can be further categorized into three subfamilies: 
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alpha-, beta- and gamma-herpesvirinae, all of which establish life-long 
infections in their hosts. Herpes simplex virus type 1 (HSV-1), varicella-zoster 
virus (VZV) of humans, and pseudorabies virus (PrV) of swine are examples of 
alphaherpesviruses. Human and mouse cytomegalovirus (HCMV and MCMV, 
respectively) are commonly studied betaherpesviruses, and Epstein-Barr virus 
(EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) are both 
gammaherpesviruses that infect humans. The virions of herpesviruses 
comprise a double stranded linear DNA genome contained within a 
proteinaceous capsid. A number of proteins surround the capsid and are 
collectively called the tegument. Surrounding the tegument is an envelope 
containing a number of viral glycoproteins. 
     Herpesviruses enter cells either by fusion at the plasma membrane or are 
endocytosed by the cell to eventually fuse within an intracellular vesicle 
(19,100,106,107,169). Regardless of how the virus enters, once the capsid 
accesses the cytosol, viral tegument proteins dissociate from the capsid to 
prime the cell for infection while the capsid traffics toward the nucleus along 
microtubules using the molecular motor dynein (32,144). Capsids migrate to 
and dock at nuclear pores where they subsequently release the viral genome 
through a unique capsid vertex (the portal) and the genome enters the nucleus 
through the nuclear pore (6,109,154). Nuclear genomes are used as templates 
for viral transcription, which occurs in three temporal stages (67,68). Nascent 
replicated genomes are then packaged into newly assembled capsids. The 
packaged capsids associate with the inner nuclear membrane and 
subsequently bud into the perinuclear space to acquire a primary envelope. 
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This envelope is lost as the virion envelope fuses with the outer nuclear 
membrane and the nucleocapsid is released in the cytosol. Next, the capsid 
associates with tegument proteins as it traffics towards the trans-Golgi network 
(TGN). TGN-derived vesicles are believed to be the major site of secondary 
envelopment where the virus acquires its final mature envelope, which is 
embedded with viral glycoproteins (158). Fusion of these transport vesicles 
with the plasma membrane releases virions into the extracellular environment. 
 
Actin and Herpesvirus Entry  
     Incoming herpesvirions first encounter host actin during entry into cells [for 
another review on herpesvirus interactions with the cytoskeleton see reference 
(85)]. The cortical actin lining the cytosolic side of the plasma membrane is a 
meshwork of F-actin connected to the cell surface through surface receptors. 
Various signaling pathways can alter the cortical actin. In the case of viral 
infection, virion glycoproteins bind to specific host cell receptors, ultimately 
causing the envelope and plasma membrane to fuse, delivering the capsid 
and tegument into the cytosol. Whereas glycoprotein D (gD) is an important 
receptor binding protein in most alphaherpesviruses except VZV, gB, gH and 
gL are all required for virion fusion (62,81,146).  
     Depending on the cell type, the fusion event required for HSV-1 entry 
occurs at a neutral pH at the plasma membrane (e.g. Hep2 and Vero cells) 
(169), through a pH-dependent endocytic pathway [e.g. HeLa cells and 
modified Chinese hamster ovary (CHO) cells expressing HSV-1 receptors] 
(107) or through a pH-independent endocytic pathway (C10 murine melanoma 
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cells) (86). Polymerized actin was shown to be dispensable for pH-
independent entry of HSV-1 into Vero cells based on insensitivity to the actin 
depolymerizing drug cytochalasin D (169). However, actin dynamics are 
required for the pH-dependent pathway utilized by HSV-1 in corneal fibroblasts 
(CF) and CHO cells, because HSV-1 entry was inhibited by cytochalasin D 
(19). Thus, the dependence of actin during entry appears to be dictated by the 
pathway of entry and type of cell infected.  
     In actin-dependent entry, initial binding to the cell surface can influence 
cortical actin. For example, binding of HSV-1 gD to the surface receptor 
nectin-1 (a member of the immunoglobulin superfamily and also known as 
HveC and CD111) stimulates Rho GTPase signaling, which in turn can alter 
the morphology of cortical actin. In cell lines such as CF, Madin-Darby canine 
kidney II (MDCKII) and CHO cells, HSV-1 entry has been shown to induce 
Cdc42 signaling (69). During entry into CHO cells expressing HSV-1 
receptors, HSV-1 virions induce and attach to protrusions from the plasma 
membrane (19). The presence of these protrusions correlates with RhoA 
activation. A model was proposed in which virions move along these 
protrusions (a process also known as “surfing”) to portions of the cell body for 
eventual entry in an actin-dependent phagocytosis-like uptake (19). 
Phagocytosis and another form of endocytosis, known as macropinocytosis, 
have many similarities. These similarities include the requirement for actin, 
Rac1 and Cdc42. In contrast, phagocytic cells (e.g. macrophages) require 
RhoA in addition to Rac1 and Cdc42 (95). Differently from the CHO cells, 
inhibition of RhoA activation did not block HSV-1 entry into MDCKII cells (69). 
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In these cells entry correlates with Cdc42 and Rac1 activation rather than 
RhoA (69). As another example of cell specific roles of actin in entry, evidence 
indicates that HSV-1 utilizes a pH-dependent endocytotic pathway to infect 
keratinocytes (106). Despite the fact that such pathways normally require 
activation of Rho GTPases, another study demonstrated HSV-1 entry into 
keratinocytes was insensitive to knock-down of Rac1, Cdc42 or RhoA. 
Therefore, entry in these cells may utilize a novel and, as of yet, unidentified 
entry pathway (114). In contrast, the gamma herpesvirus KSHV gB mediates 
entry through association with the α3β1 integrin receptor and activates Rac1, 
Cdc42 and RhoA. As might be expected from activation of these Rho 
GTPases, KSHV induces the formation of actin stress fibers, filopodia and 
ruffling within 30 minutes post infection of human foreskin fibroblast cells 
(104). 
     PrV entry into sensory neurons of the trigeminal ganglion, which is an 
important step for the establishment of latent infections, induces the formation 
of varicosities (bulges or swellings along neuronal axons) or synaptic boutons 
(27). Glycoprotein D was found to be both necessary and sufficient for 
formation of these virally-induced varicosities, and this formation was 
dependent upon Cdc42 but not Rac1 or RhoA (27). Synaptic boutons have 
also been shown to be important egress sites for both PrV (14,27) and HSV-1 
(133). 
 
Herpesviruses and Nuclear Actin  
     Once internalized into the cell, the capsid must deliver the viral genome 
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into the nucleus. Trafficking the sometimes considerable distance from the cell 
periphery to nucleus (axons of some sensory neurons are many centimeters in 
length) is mediated by microtubules and the molecular motor dynein (32,144). 
As the cell begins transcribing viral genes and replicating the viral DNA, viral 
replication compartments form and the host chromatin is marginalized to the 
nuclear periphery. The HSV-1 infected nucleus also expands at about 8 hours 
post infection (143). This nuclear expansion as well as marginalization of host 
chromosomes has been shown to require G-actin (143).  
     In HSV-1 infected Hep2 cells, nucleocapsid movement was shown to be 
sensitive to ATP depletion by sodium azide, decreased temperature, the actin 
depolymerizing agent latrunculin A and butanedione monoxime (BDM), a 
chemical inhibitor of myosin motors (43). These results suggest that 
herpesvirus nucleocapsids move toward the inner nuclear membrane in 
directed and ATP-dependent manner as opposed to free diffusion. 
Additionally, intranuclear movement was insensitive to cytochalasin D, 
implying that nucleocapsids may be utilizing non-classical actin that lacks the 
binding site for this drug. Future work is needed to determine definitively if a 
myosin motor is trafficking capsids to the nuclear periphery along F-actin, and 
if so, the specific myosin involved. 
     As a possible explanation of the mechanism of nucleocapsid intranuclear 
movement, actin filaments have been shown to form within the nucleoplasm of 
infected cells. Specifically, serial-section block-face scanning electron 
microscopy (SBFSEM) and immunofluorescence demonstrated that nuclear F-
actin closely associates with capsids in PrV infected neurons (41). Myosin Va 
 31 
 
was also found to co-localize with F-actin and GFP-labeled capsids (41). The 
direct stimulus for the generation of nuclear actin filaments during herpesvirus 
infections is unclear. It is possible that these filaments in conjunction with an 
actin motor (e.g. myosin Va or other processive myosins) provide the ATP-
dependent force for nucleocapsid movement.  
     An electron tomography study of HSV-1 nucleocapsids budding into the 
perinuclear space revealed 8-19 nm fibers resembling F-actin, which appeared 
to be connecting the capsid to the primary envelope (5). It is also possible that 
these fibers represent tegument proteins, including the nuclear envelopment 
complex containing pUL31/pUL34 or proteins associated with them. The 
nuclear envelopment complex is essential for HSV-1 budding into the 
perinuclear space (123). 
     Based on this body of evidence, it seems plausible that herpesvirus 
nucleocapsids induce nuclear F-actin polymerization and utilize or recruit a 
myosin motor to traffic capsids to the inner nuclear membrane for primary 
envelopment. 
 
Virion Egress and Actin 
     Late in infection the alphaherpesvirus kinase US3 plays a major role in 
nuclear egress, but also is responsible for depolymerizaion of actin stress 
fibers (124,139,163). In PrV infections, the US3 kinase causes both actin 
stress fiber disassembly and the generation of actin-containing cellular 
extensions in sparsely seeded swine testicle cells (40). These cellular 
extensions did not form with a US3-null virus or in cells treated with the actin-
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stabilizing drug jasplakinolide (40). These protrusions are important for cell to 
cell spread, particularly in sparsely seeded cells (40). The US3 kinase has 
been shown to bind and phosphorylate (activate) group A p21-activated 
kinases (PAKs), which are downstream effectors of Cdc42/Rac1 Rho GTPase 
signaling pathways (160). In mouse embryo fibroblasts (MEFs), US3-mediated 
disassembly of actin stress fibers required PAK2 and the formation of cellular 
projections required PAK1 (160). Sparsely seeded MEFs derived from PAK1 
knock-out mice resulted in reduced PrV spread, but PAK1 was dispensable for 
viral spread in monolayers, while MEFs derived from PAK2 knock-out mice 
were impaired for PrV spread in both sparsely seeded and MEF monolayers 
(160). It is tempting to speculate that the US3-induced cell extensions may be 
important primarily when infected cells are not in direct contact with 
neighboring target cells. The contribution of these extensions for virus spread 
in vivo requires further study. 
     Actin has been shown to be present in purified herpesviruses. How this 
incorporation takes place as well as its potential role in infection is unknown. It 
is possible that the presence of F-actin in virions plays a structural role, since 
incorporation was enriched in PrV virions lacking tegument components 
(28,99,171). 
     Myosin motors have also been shown to be involved in viral egress. In 
HSV-1, the tegument protein VP22 has been shown to interact with non-
muscle myosin IIA (NMIIA) (161). Additionally, treatment of Vero cells with the 
myosin inhibitor BDM at 12 hpi reduced HSV-1 secretion 20-fold and had little 
effect on the amount of cell-associated virus produced (161). NMIIA is a non-
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processive motor that regulates F-actin by cross-linking and contracting actin 
filaments (22,162). It has also been shown to be important for fusion pore 
expansion during exocytosis, which could have implications for virions as they 
escape from the TGN-derived vesicles and enter the extracellular environment 
(105). Recently NMIIA and F-actin, along with Rab6, were shown to be 
required for the fission of vesicles emerging from the Golgi complex (101). In 
cells where NMIIA or Rab6 were inhibited or knocked down, tubules were 
observed to emanate from the Golgi apparatus representing unfissioned 
budding vesicles. Protein kinase D (PKD) has been similarly described as 
required for membrane fission at the TGN (9) and for HSV-1 egress (120). 
This presents the possibility that NMIIA, along with Rab6 and PKD, is 
important for generating vesicles distinct from the Golgi that are free to traffic 
to the plasma membrane for virion release. Inhibition of NMIIA would prevent 
these vesicles from severing, but would likely not decrease intracellular 
infectivity (assuming the unfissioned, emerging tubules are competent for viral 
budding), consistent with previous observations (161). 
     Myosin Va (myoVa) is known to be important for secretion of melanosomes 
(174) and secretory granules (130) by providing transport through cortical F-
actin. The transition between microtubule filaments and cortical actin has been 
described as a “capture” process where the microtubule motor kinesin traffics 
cargo to the cell periphery where myoVa is required for association of the 
cargo within the cortical actin and eventually secretion. MyoVa has also been 
linked to HSV-1 secretion as well as cell surface expression of at least gD, gB 
and gM (126). In this study, two red fluorescent protein (RFP)-tagged 
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dominant-negative isoforms (brain and skin) of myoVa were expressed during 
HSV-1 infection. Secretion of infectivity was down 50-75% compared to control 
cells expressing RFP alone. Under the same conditions, surface expression of 
gD, gB and gM were significantly decreased compared to RFP expressing 
control cells. It is possible that egressing virions within TGN-derived vesicles 
could behave similarly to other myosin dependent cargo. In this model, kinesin 
delivers virion-laden vesicles to cortical actin and myoVa transports the 
vesicles the remaining short distance to the plasma membrane for fusion.  
Thus, both NMIIA and myoVa may be involved in functionally distinct and 
important steps during egress of HSV-1 and likely other herpesviruses. Further 
work is needed to test the models proposed above and to fully understand the 
roles of actin and myosin motors during herpesvirus infections. 
 
Conclusion 
     Like all viruses, herpesviruses are obligate, intracellular pathogens relying 
on host machinery to replicate and spread. Actin plays a critical and diverse 
role in the cell and in the lifecycle of herpesviruses. In this way, virology 
research is useful not only for expanding our understanding of how viruses 
function, but help reveal the intricate biology of our own cells. Many details 
about the interaction of herpesviruses with actin remain to be investigated. For 
example, it would be of interest to know what specific viral proteins interact 
with host myosin motors and how myosin-driven activities are regulated during 
infection. Nuclear actin is an emerging area of study in virology, as well as cell 
biology. A better understanding of how nuclear F-actin formation is triggered 
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and how it contributes to viral infection would be of great interest to both fields. 
Elucidating the mechanism behind the ATP-, F-actin and possibly myosin-
dependent movement of nucleocapsids would be an important discovery for 
nuclear trafficking events. Undoubtedly, much remains to be learned from the 
interplay of virus and host. 
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Figure 2.2 Model of herpesvirus entry, maturation and egress. (A) Herpes 
virion “surfing” towards the plasma membrane along membrane protrusions for 
entry. (B) Capsid trafficking toward the nuclear periphery for budding via a 
myosin motor on F-actin. (C) US3-mediated depolymerization of actin stess 
fibers. (D) US3-mediated generation of membrane projection and cell-to-cell 
spread of herpesvirus. (E) Myosin IIA- and Rab6-dependent fission of nascent 
vesicles from the Golgi body. (F) Enveloped virion within a TGN-derived 
vesicle trafficking through cortical actin via myosin Va toward the plasma 
membrane for secretion. 
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CHAPTER III 
 
Myosin Va enhances secretion of herpes simplex virus 1 virions and cell 
surface expression of viral glycoproteins*  
 
Kari L. Roberts and Joel D. Baines, Department of Microbiology and 
Immunology, Cornell University, Ithaca, NY 14853. 
 
 
 
 
 
 
 
 
 
 
 
 
*Reprinted from Roberts, KL, J.D. Baines. (2010). Myosin Va enhances 
secretion of herpes simplex virus 1 virions and cell surface expression of viral 
glycoproteins. J Virol 84:9889-9896. Copyright © 2010, The American Society 
for Microbiology. 
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Abstract 
 The final step in the egress of herpes simplex virions requires virion-laden 
vesicles to bypass cortical actin and fuse with the plasma membrane, 
releasing virions into the extracellular space. Little is known about the host or 
viral proteins involved. In the current study, we noted that the conformation of 
myosin Va (myoVa), a protein known to be involved in melanosome and 
secretory granule trafficking to the plasma membrane in melanocytes and 
neuroendocrine cells, respectively, was altered by four hours after infection 
with HSV-1 such that an N-terminal epitope expected to be masked in its 
inactive state was rendered immunoreactive. Wild type myoVa localized 
throughout the cytoplasm and to a limited extent in the nucleus of HSV-
infected cells. Two different dominant negative myoVa molecules containing 
cargo-binding domains but lacking the lever arms and actin-binding domains 
co-localized with markers of the trans-Golgi network. Expression of dominant 
negative myoVa isoforms reduced secretion of HSV-1 infectivity into the 
medium by 50-75%, reduced surface expression of glycoprotein B, M and D 
and increased intracellular virus infectivity to levels consistent with increased 
retention of virions in the cytoplasm. These data suggest that myoVa is 
activated during HSV-1 infection to help transport virion- and glycoprotein-
laden vesicles from the TGN, through cortical actin, to the plasma membrane. 
We also cannot exclude a role for myoVa in promoting fusion of these vesicles 
with the inner surface of the plasma membrane. These data also indicate that 
myoVa is involved in exocytosis in human epithelial cells as well as other cell 
types. 
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Introduction 
 Herpes simplex virus virions, like those of all herpesviruses, comprise a lipid 
envelope surrounding a layer of proteins called the tegument that covers the 
surface of the proteinaceous DNA-containing capsid. After assembly in the 
nucleus, herpes simplex virus nucleocapsids bud through the inner nuclear 
membrane to obtain an initial virion envelope. In the most widely accepted 
model of virion egress, the envelopes of nascent virions residing in the 
perinuclear space then fuse with the outer nuclear membrane, releasing the 
de-enveloped capsid into the cytoplasm (147). The now cytosolic capsid then 
buds into a membranous organelle in the cytoplasm to obtain its final 
envelope. The site of secondary envelopment where the final budding event 
occurs is believed to contain markers of the trans-Golgi network (158) and 
would be expected to contain the full complement of virion envelope and 
tegument proteins. Cellular budding machinery would also be expected to be 
involved, such as that required for multivesicular body formation (10,25). Other 
models of virion egress propose that nucleocapsids can exit the nucleus 
through an expanded nuclear pore (167,168), or that the original virion 
envelope derived from the inner nuclear membrane is retained throughout 
egress (71). In the latter scenario, enveloped virions are incorporated into a 
vesicle derived from the outer nuclear membrane. This model is not consistent 
with the observations that a membrane protein encoded by UL34 along with its 
tegument binding partner encoded by UL31 are present in perinuclear virions, 
but absent from extracellular virions (44,124).  
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 Regardless of the prior steps involved, all models of virion egress propose a 
similar final step, namely that vesicles bearing one or more complete 
enveloped virions are transported to and fuse with the plasma membrane, 
releasing the virions into the extracellular space. The extent to which this final 
exit step contributes to the life cycle is virus and cell type dependent. For 
example, approximately 10% of total infectivity is secreted into the 
extracellular space of cultured Vero cells infected with herpes simplex virus 1 
(HSV-1), whereas Varicella Zoster Virus remains almost completely cell 
associated in cultured MeWo cells (12). Despite general agreement that it 
occurs, the mechanism by which the virion-laden vesicles are transported to 
the plasma membrane has not been studied extensively. Myosin Va (myoVa) 
is a good candidate to mediate such transport because this motor has been 
shown to be important for the egress of melanosomes (174) and secretory 
granules (130) by facilitating their transport through the cortical filamentous 
actin (F-actin) located beneath the plasma membrane. The mechanism 
underlying this vesicle transport  has been described as a “dual transport“ 
process whereby cargoes brought to the cortex via microtubule-associated 
motors (such as kinesin) are subsequently transferred to cortical F-actin. 
Egress is then facilitated by myoVa (174) which moves along F-actin by 
processive (consecutive) “hand over hand” steps through a series of ATP 
hydrolysis reactions [for review see (56,159)]. The motor consists of two heavy 
chains that dimerize to form duplicate N terminal head domains (the actin- and 
nucleotide-binding region) extending into lever arms, a single coiled-coil 
dimerization tail domain, and two C-terminal globular tail domains (GTDs), 
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which are believed to bind cargo.  
 The RNA encoding the tail domain of myoVa is alternatively spliced (141,150), 
causing variations in different isomers encoded by exons B, D and F 
(encoding 3, 27 and 25 amino acids, respectively). Cargo recognition can be 
regulated by interactions between various effector proteins, including Rab 
family GTPases and different myoVa exons. Specifically, exon F is required for 
interaction with Rab27a (173), exon B is necessary to interact with dynein light 
chain 2 (DLC2) (64,165), and exon D is essential to bind Rab10 (127). 
Additionally, Rab11 is known to interact with class V myosins (24). Mutations 
in the human myoVa gene is the cause of Griscelli syndrome, which can 
manifest with severe neurological impairment and/or hypopigmentation 
depending on the locus of the mutation (94,112).  
 Given its known role in vesicle secretion, the current study investigates a 
potential role for myoVa in the secretion of HSV-1 virions. In the course of 
these studies, dominant negative myosin Va (DN-myoVa) constructs were 
used. These contained the exon-encoded portion of the myoVa tail domain as 
well as the entire (~400 amino acids) GTD. To address the effects of 
alternative splicing, and by extension, involvement of different effectors in 
secretion, we used two DN-myoVa constructs. The MCLT (from melanocyte 
long tail) construct contained exons D and F but lacked exon B, whereas the 
brain long tail (BRLT) construct contained exon B, but not D or F.  
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Materials and Methods 
Viruses and Cells 
 Wild type HSV-1 strain F (HSV-1[F]) and HSV-1 UL13 deletion virus (R7355) 
were kindly provided by Bernard Roizman and have been described previously 
(35,124). vRR1204 (a kind gift from Richard Roller) contains a lysine to 
alanine mutation at codon 220 in the US3 open reading frame that precludes 
its kinase activity (131). The K26 virus, kindly provided by Prashant Desai, 
encodes a VP26 capsid protein fused to GFP. Virus stocks were propagated 
and titered on Vero cell monolayers, which  were maintained in growth 
medium, consisting  of Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 125 units/mL penicillin, 0.125 mg/mL streptomycin and 
10% newborn calf serum. After infection, cells were overlayed with 199V 
medium (DMEM supplemented with 1% newborn calf serum) and monitored 
for cytopathic effects. To release intracellular virus, the cells were lysed by 
freezing and thawing.  
 
Plasmids and Transfections 
 Dominant negative myosin Va (DN-myoVa) constructs contained the exon-
encoded portion of the myoVa tail domain as well as the GTD. MCLT stands 
for Melanocyte Long Tail. BRLT stands for Brain Long Tail. Both isoforms 
were kindly provided by Dr. John Hammer III. 
 The dominant negative myoVa isoforms were excised from their supplied 
vectors by digestion at flanking Not-I restriction sites and ligated into Not-I 
digested pcDNA3 (Invitrogen). Monomeric red (mRED) was amplified by 
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polymerase chain reaction (PCR) such that the amplicon ends contained 
HindIII/EcoRI sites and a mutation changing the stop codon to alanine. 
Primers used for this purpose were:  
5’-AAAAAGCTTATGGCCTCCTCCGAGGACG-3’  
Rev primer:  
5’-AAAGAATTCCCTGCGGCGCCGGTGGAGTGGCGG-3’.  
The amplicon was ligated into the respective pcDNA3 constructs in frame with 
the 5’ ends of the MCLT and BRLT open reading frames. The genotypes of 
plasmid DNAs were verified by DNA sequencing. 
 For transfections, cells were transfected when they were approximately 90% 
confluent with approximately 1.6 μg of plasmid DNA per well in 12-well dishes 
or 4.0 μg of plasmid DNA per well in 6-well dishes using Lipofectamine 2000 
(Invitrogen) according to the directions of the manufacturer. 
 
Immunofluorescence  
     At 28.5 hours post transfection, the cells were either mock infected or 
infected with 5.0 PFU/cell of HSV-1(F) or 10 PFU/cell with HSV-1 K26 as 
indicated. The cells were washed once with phosphate buffered saline (PBS), 
fixed in 3% paraformaldehyde (PFA) for 15 minutes, and autofluorescence 
was quenched by immersion in 50 mM NH4Cl for 15 minutes. In some 
experiments, the cells were permeabilized with 0.1% Triton-X 100 for 2 
minutes followed by a 10 minute block in 10% human serum in PBS. When 
probing for surface gD, all the steps remained the same, except treatment with 
Triton-X 100 was omitted. Goat anti-Myosin Va (1:50, Santa Cruz 
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Biotechnology), rabbit anti-Myosin Va (1:50, Santa Cruz Biotechnology), 
mouse anti-ICP4 (1:100, Rumbaugh-Goodwin Institute for Cancer Research, 
Plantation, FL), rabbit anti-ICP8 (1:500, a kind gift from Bill Ruyechan), mouse 
anti-TGN38 (1:100, BD Transduction Labs cat. no. 610898), and mouse anti-
Golgi 58K (1:100, Abcam cat. no. ab6284) primary antibodies were prepared 
in a 1% bovine serum albumin (BSA)/PBS solution. The mouse anti-gD (DL-6) 
monoclonal antibody (kindly provided by Roselyn Eisenberg and Gary Cohen) 
and rabbit anti-gB (kindly provided by David Johnson) was diluted in 1% 
BSA/PBS 1:100 (or 1:200 in permeabilized cells for gD). The rabbit anti-gM 
antibody was diluted 1:500 in 1% BSA/PBS. All primary antibodies were 
incubated with the fixed cells for 30-60 minutes in a humidity chamber held at 
room temperature. After washing 3 times in PBS, the cells were reacted for 
30-60 minutes in a humidity chamber with secondary antibodies FITC-
conjugated anti-goat or FITC-conjugated anti-mouse and/or Texas Red or Cy5 
conjugated anti-rabbit IgG (Jackson Laboratories) diluted 1:100 in 1% 
BSA/PBS. The coverslips were then rinsed 3 times in PBS and dipped in 
ddH20 before mounting on glass slides with mowiol plus 2.5% DABCO to 
prevent photobleaching. All digital images except for those used for surface 
gD quantification were taken using an IX70 Olympus confocal microscope and 
were processed with Adobe Photoshop software. Digital images for gD 
quantification were taken using a Zeiss Axio Imager.M1 fluorescent 
microscope and analyzed with IP Lab v3.65a software from Scanalytics.  
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Immunoblot Analyses 
 Mock infected and HSV-1(F) infected HEp-2 cells were washed once in PBS 
then lysed in 100 μL of 2X sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) sample buffer (100 mM TrisCl [pH 6.8], 200 mM 
dithiothreitol, 4% SDS, 20% glycerol, 0.2% bromophenol blue). Lysates were 
sonicated and boiled for 5 minutes prior to loading. Samples were separated 
on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane (30 
volts for 3.5 hours at 4°C). The membrane was blocked in 5% milk/TBST (1X 
tris-buffered saline plus 0.1% Tween) for 1 hour at room temperature. Primary 
antibodies: goat anti-myoVa (1:200, Santa Cruz Biotechnology), rabbit anti-
ICP8 (1:10000) and mouse anti-lamin A/C (1:1000, Santa Cruz 
Biotechnology). Bound primary antibody was detected by addition of anti-goat 
or anti-rabbit (1:2000, Santa Cruz Biotechnology) horseradish peroxidase-
conjugated secondary antibody diluted in 5% milk/TBST and visualized by 
enhanced chemiluminescence (Pierce) followed by exposure to X-ray film 
(Pierce).  
 
Analyses of Virion Egress  
 HeLa cells were transfected as described above. At 15-28 hours post 
transfection, approximately 0.1 PFU HSV-1(F) per cell in 1 mL 199V was 
added to each well. The cells were incubated for 1 hour at 37°C with gentile 
agitation and subsequently washed 3 times with versene (1X PBS and 0.5 mM 
ethylenediaminetetraacetic acid [EDTA]) and once with a low pH buffer (40 
mM citric acid [pH 3.0], 10mM KCl, 135 mM NaCl) to inactivate any residual 
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infectitivity. This overlay was then removed and 1.5 mL of 199V was added to 
each well. The 0 hpi time point samples were collected immediately and the 
remaining samples were incubated at 37°C/5% CO2 for another 20 hours. To 
assess infectivity, parallel cultures of cells and/or overlaying medium was 
freeze-thawed to release virus, diluted serially, and subjected to plaque assay 
on Vero cell monolayers. To check expression of the myoVa constructs, total 
cell lysates of infected HeLa cells beneath collected supernatants were 
collected and analyzed by immunoblot as described above. Rabbit anti-RFP 
antibody (1 μg/mL, GenScript) was used to detect expression of mRED-DN-
myoVa MCLT, mRED-DN-myoVa BRLT, and mRED.  
 
Glycoprotein surface expression analysis 
     HEp-2 cells expressing either mRED, mRED-DN-myoVa BRLT or mRED-
DN-myoVa MCLT were infected with HSV-1 K26-GFP (MOI=10 PFU/cell) or 
mock infected and fixed in 3% PFA at 17 hpi. Fixed cells were immunostained 
without permeabilization as described above. At least 50 infected cells 
expressing each construct type were digitally recorded using a Zeiss 
Imager.M1 Axio fluorescent microscope and the images were analyzed to 
quantify surface gD expression using IP Lab v6.35a software from Scanalytics, 
Inc. 
 
Results 
Immunoreactivity of Myosin Va is increased during HSV-1 Infection.  
     The intracellular environment of host cells is highly viscous and not 
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conducive to free diffusion of HSV-1 particles [for review see (85)]. Myosin Va 
(myoVa) is an unconventional actin motor which, through ATP hydrolysis, 
moves cargo along polar actin fibers towards the plus (or barbed) end. In an 
effort to determine if HSV-1 utilizes this actin motor, we performed 
immunofluorescence assays to reveal the localization of myoVa in HSV-1(F) 
infected and mock infected HEp-2 cells. Cells were seeded onto coverslips in 
a 12-well dish and infected with wild type HSV-1(F) or were mock infected. At 
0, 4, 10, 16 and 22 hours post infection (hpi), cells were washed with PBS and 
fixed in 3% paraformaldehyde (PFA). Fixed cells were permeabilized in 0.1% 
Triton-X 100, blocked in 10% human serum and were immunostained with 
goat anti-myoVa and rabbit anti-ICP8 antibodies.  
 As shown in figure 3.1, the amount of myoVa immunoreactivity increased 
extensively during the course of infection. This increase was first detectable at 
4 hpi, and increased significantly by 16 hpi. MyoVa immunoreactivity localized 
primarily to the cytoplasm at these time points, although some cells 
demonstrated substantial intranuclear immunostaininig. By 22 hpi, myoVa 
immunostaining localized primarily to infected nuclei.  Similar results were 
obtained using Vero and HeLa cells (figure 3.2).  
 
Steady state levels of Myosin Va Protein are Unchanged in HSV-Infected 
Cells. 
     To determine whether or not the increased immunoreactivity reflected an 
increase in steady state levels of myoVa, we analyzed the amount of myoVa  
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Figure 3.1 Immunoreactivity of myosin Va is increased during HSV-1 
infection. HEp-2 cells were mock infected or infected with 5 PFU HSV-1(F) 
per cell and fixed at 4, 10, 16 and 22 hpi. Cells were washed with PBS and 
fixed in 3% paraformaldehyde (PFA) for 15 minutes and permeabilized with 
0.1% Triton-X 100. The fixed permeabilized cells were immunostained with 
goat anti-myoVa and rabbit anti-ICP8 antibodies. Single sections of 
immunostained cells were digitally collected with an Olympus confocal 
microscope. Green: anti-myosin Va; red: anti-ICP8. 
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Figure 3.2 Immunoreactivity of myosin Va is increased during HSV-1 
infection in multiple cell types. HeLa and Vero cells were mock infected or 
infected with 5 PFU HSV-1(F) per cell and fixed at 6 hpi. Cells were washed 
with PBS and fixed in 3% PFA for 15 minutes and permeabilized with 0.1% 
Triton-X 100. The fixed permeabilized cells were immunostained with goat 
anti-myoVa and rabbit anti-ICP8 antibodies.  Single sections of immunostained 
cells were digitally collected with an Olympus confocal microscope.  Green: 
anti-myosin Va; red: anti-ICP8.
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protein in total cell lysates of mock infected or HSV-1(F) infected HeLa cells 
(collected over several time points) by immunoblot assay. We also probed the 
immunoblot with antibodies to ICP8 and lamin A/C as an infection control and 
loading control, respectively.  
 As shown in figure 3.3, similar levels of myoVa were detected in mock and all 
HSV-1(F) infected cell lysates collected at five different time points. Since 
phosphorylation can also play a role in epitope recognition and activation of 
myosins, we examined cells infected with a US3 kinase-dead mutant HSV-1 
(131) as well as an HSV-1 mutant lacking the UL13 kinase (118) by 
immunofluorescence. Fluorescent signals from the myoVa antibody were 
similar to that of HSV-1(F) in both mutant backgrounds (figure 3.4), indicating 
that these viral kinases were not responsible for the conformational change in 
myoVa. 
 
A Myosin Va Epitope is Exposed Preferentially in HSV-Infected Cells. 
     The goat polyclonal antibody used above is directed against (Santa Cruz 
Biotechnology, sc-17707) an epitope within the N-terminal motor domain of 
myoVa (amino acids 117-137). This epitope is located near an N terminal 
region that interacts with a C-terminal domain to hold the myosin molecule in 
the folded (inactive) conformation. We therefore asked whether a second 
myoVa antibody binding to an epitope that would be exposed in both the 
folded (inactive) and extended (active) conformations would produce similar 
levels of fluorescent intensity upon immunostaining mock- and HSV-infected  
 
 52 
 
 
 
 
Figure 3.3 Steady state levels of myosin Va protein are unchanged in 
HSV-infected cells. Immunoblot showing levels of myosin Va in mock and 
HSV-1(F) infected HEp-2 total cell lysates. Cells were mock infected or 
infected with 5 PFU per cell HSV-1(F), lysed in 2X denaturing buffer at 18 hpi, 
and proteins were separated on a polyacrylamide gel and transferred to 
nitrocellulose. The blots were probed with a goat anti-myoVa antibody and 
rabbit anti-ICP8 antibody. Immunoreactivity of goat anti-lamin B antibody 
served as a loading control. 
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Figure 3.4 Viral kinases pUS3 and pUL13 are not required for increased 
immunoreactivity of myosin Va during HSV-1 infection. HEp-2 cells were 
mock infected or infected with HSV-1(F), US3 kinase dead or ΔUL13 and fixed 
at 18 hpi. Cells were immunostained and photographed as described in figure 
3.1.  Green: anti-myosin Va; red: anti-ICP8.
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cells. To address this possibility, HeLa cells were either mock infected or HSV-
1 infected and co-immunostained with the original goat polyclonal antibody to 
myoVa, and a second polyclonal antibody made in rabbits that binds to amino 
acids 981-1070 (Santa Cruz Biotechnology, sc-25726) in the myoVa tail 
dimerization domain. The cells were also Immunostained with a mouse anti-
ICP4 antibody to mark infected cell nuclei. The results are shown in figure 3.5. 
     Examination of the immunostained cells by confocal microscopy revealed 
that the tail-specific myoVa antibody stained mock and HSV-infected cells 
similarly (red), whereas the previous myoVa antibody recognizing the N-
terminal epitope (green) preferentially stained HSV-infected cells. These data, 
taken together with that shown in figure 3.3, suggest that the increase in 
myoVa immunoreactivity results from unmasking of the myoVa epitope rather 
than an increase in protein level. We speculate that this unfolding reflects 
activation of myoVa in HSV-infected cells.  
 
DN-MyoVa Co-localizes primarily with the TGN in HSV-1(F) Infected Cells.   
     Because HSV-1 virions are  thought to transit  into or near the trans-Golgi 
network (TGN) on their way to the extracellular space (158), we hypothesized 
that expression of a dominant negative myoVa motor would block HSV-1 virion 
secretion by inhibiting virion-laden TGN vesicles from passing through cortical 
F-actin. One prediction of this hypothesis is that dominant negative myoVa 
would localize at the TGN because the globular domain would bind to these 
vesicles and the absence of the actin-binding domain would preclude  
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Figure 3.5 A myosin Va epitope is exposed preferentially in HSV-infected 
cells. HeLa cells were mock infected or infected with HSV-1(F) (MOI = 5 PFU 
per cell). At 16 hpi the cells were washed in PBS, fixed in 3% PFA for 15 
minutes and permeabilized with 0.1% Triton-X 100. Fixed cells were 
immunostained with rabbit anti-myosin Va (top row) or goat anti-myosin Va 
(center row). Mouse antibody to ICP4 was used to mark infected cell nuclei. 
Red: myoVa (epitope in tail region); green: myoVa (epitope in N terminal 
region); blue: ICP4.
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movement to the plasma membrane. To test this prediction, we transfected 
HeLa cells with the mRED-DN-myoVa constructs and compared localization of 
mRED-DN-myoVa to TGN and Golgi markers. The results are presented in 
figure 3.6. 
     At high PMT levels or in stacked images, the mRED and DNmyoVa 
constructs localized throughout the cytoplasm, making it difficult to discern the 
predominant localization of the proteins. At lower PMT settings, image slices 
taken with a confocal microscope showed that the mRED-DN-myoVa isoforms 
concentrated within cytoplasmic puncta that were not present in the mRED-
expressing control cells. Some of these puncta co-localized with sites 
containing substantial immunostaining with the TGN38 marker. We did not see 
substantial co-localization between cytoplasmic foci bearing high 
concentrations of mRED-DN-myoVa isoforms and markers of the Golgi 
apparatus, although some overlap of the immunostaining was apparent even 
at low PMT settings. We found similar results in HEp-2 cells (figure 3.7). The 
data indicate that the DN-myoVa isoforms localize primarily at the TGN, and to 
a much lesser extent at the Golgi apparatus.  
 
Myosin Va is Required for Efficient Secretion of HSV-1 infectivity, but not 
for production of intracellular infectivity. 
     To test our hypothesis that DN-myoVa impacts virion secretion, we 
transfected HeLa cells with the mRED-DN-myoVa isoforms and mRED control 
constructs and infected the cells the next day with HSV-1(F) at an MOI of 0.1  
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Figure 3.6 DN-myoVa co-localizes with TGN but not Golgi markers in 
HSV-infected HeLa cells. HeLa cells were transfected with mRED-DN-
myoVa BRLT (left column), MCLT (center and right column). At 23 hours post 
transfection the cells were infected with HSV-1(F) at an MOI of 5 PFU per cell. 
At 16 hpi the cells were washed with PBS, fixed in 3% PFA for 15 minutes, 
and permeabilized with 0.1% Triton-X 100. Fixed cells were immunostained 
with mouse anti-TGN (top row, first and second columns) or mouse anti-Golgi 
markers (top row, right column). Rabbit anti-ICP8 was used to mark the 
infected cell nuclei. Red: DN-myoVa; green: TGN and Golgi; blue: ICP8. 
Arrows indicate sites of co-localization of the respective markers.
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Figure 3.7 DN-myoVa co-localizes with TGN but not Golgi markers in 
virus infected HEp-2 cells. HEp-2 cells were transfected with mRED-DN-
myoVa BRLT (upper row), MCLT (second row from top and bottom row), or an 
mRED control construct (third row from top), and at 28.5 hours post 
transfection were infected with HSV-1(F) at an MOI of 5. At 15.5 hpi cells were 
washed with PBS, fixed in 3% PFA for 15 minutes, and permeabilized with 
0.1% Triton-X 100.  Fixed cells were immunostained with mouse anti-TGN (top 
3 rows) or mouse anti-Golgi markers (bottom row). Rabbit anti-ICP8 was used 
to mark the infected cell nuclei.  Red: DN-myoVa or mRED control; green: 
TGN and Golgi; blue: ICP8. Arrows indicate sites of co-localization of the 
respective markers. 
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PFU per cell. After virus adsorption for 1 hour, the cells were washed 3 times 
with PBS and once with a low pH buffer to neutralize any remaining 
extracellular infectivity. At this time and again 20 hours later, we collected the 
199V overlay medium containing secreted virions as well as total cell lysates 
of the infected cell monolayers beneath the 199V. At the same time points, the 
remaining cultures containing intracellular virus and medium overlay were 
subjected to freeze-thawing to release intracellular infectivity. The infectivity 
was then measured by plaque assay. The expression of the dominant 
negative and control constructs were monitored in parallel by immunoblot 
analysis. 
 As shown in figure 3.8A, the levels of the MCLT and BRLT isoforms were 
detected as high molecular weight bands (approximately Mr 130,000) that 
reacted with rabbit anti-RFP antibody, indicating fusion of the fluorescent tag 
to the construct. MCLT ran slightly slower than BRLT, which was due to the 
additional exons contained in the MCLT transcript. A band indicative of mRED 
was detected in lanes containing lysates of the control cells.  
 As shown in figure 3.8B, at 0 hpi almost no residual HSV-1 infectivity was 
detected inasmuch as the highest titer was 1 PFU per cell. At 20 hpi, secreted 
infectivity from the mRED-DN-myoVa BRLT and MCLT transfected cells was 
lower than the level of infectivity released from cells transfected with the 
mRED control vector (approximately 51% and 25% of the control, 
respectively). In contrast, the intracellular infectivity in the BRLT and MCLT 
expressing cells were higher than the infectivity from mRED expressing control 
cells (approximately 183% and 172% of the control, respectively). Table 3.1  
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Figure 3.8 Myosin Va is required for efficient secretion of HSV-1 virions, 
but not for intracellular production of infectivity. (A) HeLa cells were 
transfected with expression vectors for mRED-DN-myoVa-BRLT, mRED-DN-
myoVa-MCLT or mRED alone. Total cell lysates were collected at 26 hours 
post transfection, separated on a polyacrylamide gel and transferred to 
nitrocellulose. The blots were probed with a rabbit anti-RFP antibody. Signals 
from goat anti-lamin B antibody served as loading controls. (B) HeLa cells 
were transfected with expression vectors for mRED-DN-myoVa-BRLT, mRED-
DN-myoVa-MCLT or mRED alone. At 26 hours post transfection, cells were 
infected with HSV-1(F) at an MOI of 0.1. The resulting infectivity was 
determined by titration on Vero cells. The graph represents averages of data 
collected from three separate experiments.
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lists the amount of infectivity determined in three separate trials. We interpret 
these data to indicate that the DN-myoVa blocks release of HSV-1 virions, but 
not the accumulation of infectious virus within cells.  
 
Expression of DN-myoVa Results in Decreased Glycoprotein 
Presentation on the Surface of HSV-Infected Cells.  
     To determine if secretion of cargo other than virions required myoVa, we 
asked whether or not the mRED-DN-myoVa constructs could preclude viral 
glycoprotein transport to the cell surface. We therefore transfected HEp-2 cells 
with the dominant negative BRLT and MCLT isoforms or the mRED control 
vector. At 24 hours post transfection the cells were mock infected or infected 
with 10 PFU per cell of HSV-1 K26-GFP, a virus that encodes a VP26 capsid 
protein fused to GFP. The cells were subjected to analysis by indirect 
immunofluorescence as indicated above except that they were fixed with PFA 
in the absence of detergent. To monitor glycoprotein expression at the cell 
surface, we reacted these unpermeabilized cells with DL6 monoclonal 
antibody that recognizes a luminal epitope of HSV-1 envelope protein gD, gB 
antibody or gM antibody and examined the cells by fluorescent microscopy. 
The results are presented in figure 3.9. 
     Cells infected with HSV-1 K26-GFP were indicated by the presence of 
intrinsic bright GFP-mediated fluorescence in their nuclei as described 
previously (29). Uninfected cells did not display notable gD-specific 
fluorescence, as expected. In contrast, high amounts of glycoprotein-specific  
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Table 3.1 Total and secreted HSV-1 infectivity. The table lists titrations of 
infectivity from all three experiments shown in Figure 5B.  These data were 
normalized to wild type values and used in the bar graph of Figure 5B. 
Titrations were performed by plaque assay on Vero cell monolayers. 
 
20hpi Total Infectivity 20hpi Secreted Infectivity
PFU/mL mRED BRLT MCLT PFU/mL mRED BRLT MCLT
trial 1 1.0E+03 2.0E+03 2.0E+03 trial 1 2.0E+01 8.0E+00 4.0E+00
trial 2 3.0E+02 8.0E+02 6.0E+02 trial 2 1.1E+01 7.0E+00 5.0E+00
trial 3 2.3E+02 1.9E+02 2.7E+02 trial 3 1.0E+01 5.0E+00 1.0E+00
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Figure 3.9 Expression of DN-myoVa decreases glycoprotein 
immunoreactivity on the surface of HSV-infected HEp-2 cells. (A)HEp-2 
cells were transfected with either mRED-DN-myoVa-BRLT, mRED-DN-
myoVa-MCLT or mRED control vector. Transfected cells were infected with 
HSV-1 K26-GFP (MOI = 10 PFU per cell) or mock infected at 26 hours post 
transfection. At 15.5 hpi the cells were washed with PBS, fixed in 3% PFA for 
15 minutes and blocked in 10% human serum. The fixed, unpermeabilized 
cells were immunostained with a gD monoclonal antibody.K26 infected cells 
expressing either the mRED control, mRED-DN-myoVa BRLT or mRED-DN-
myoVa MCLT were identified at random by intrinsic red and GFP 
fluorescence, and the amount of gD-spcecific fluorescence was quantified 
using a Zeiss Imager.M1 Axio fluorescent microscope and IP Lab v3.65a 
software. At least 50 infected cells expressing each construct were analyzed. 
Mean fluorescence is the sum of measured fluorescence divided by the area. 
The mRED-DN-myoVa BRLT- and MCLT-expressing cells were found to have 
less surface expression of gB, gM and gD as compared to mRED control cells 
by Student’s T test (p < 0.05). (B) Example of K26 infected cells transfected 
with DN-myoVa or the mRED control demonstrating decreased 
immunoreactivity with gD antibody in DN-myoVa expressing cells. White 
arrows indicate cells of interest. Green: HSV-1, blue: gD, red: DN-myoVa or 
mRED control. 
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immunofluorescence were noted in unpermeabilized cells infected with the 
K26-GFP virus and expressing the mRED control. In infected cells expressing 
the mRED-DN-myoVa constructs, considerably less glycoprotein-specific 
immunoreactivity was detected on the cell surface. 
 Glycoprotein surface expression was quantified in infected cells expressing 
mRED or the mRED-DN-myoVa constructs by analysis of digital images of at 
least 50 infected cells (i.e. exhibiting GFP fluorescence) expressing each 
mRED or mRED-DN-myoVa construct  using IP Lab v3.65a software. The 
quantification data is presented in figure 3.9A and indicates significantly less 
surface expression of gB, gM and gD on cells expressing both mRED-DN-
myoVa constructs compared to those expressing mRED alone (p <0.05 by 
student’s T test). To demonstrate that DN-myoVa expression did not preclude 
expression we repeated this experiment under similar conditions, but 
permeabilized the cells with detergent and probed with the gD antibody. We 
found readily detectable levels of gD within the permeabilized infected mRED-
DN-myoVa expressing cells (figure 3.10). Taken together, the data suggest 
that myoVa plays a role in surface expression of viral glycoproteins. 
 
Discussion 
     MyoVa has been implicated in transport of secretory granules and 
melanosomes to the cell surface of neuroendocrine cells (33,130) and 
melanocytes, respectively (174). Through the use of two different dominant 
negative myosin Va (DN-myoVa) constructs lacking the actin-binding domain  
 68 
 
 
Figure 3.10 mRED-DN-myoVa expression does not preclude gD 
expression. HEp-2 cells were transfected with either mRED-DN-myoVa-
BRLT, mRED-DN-myoVa-MCLT or mRED control vector. At 30 hours post 
transfection, the cells were infected with 5.0 PFU per cell of HSV-1(F). At 15.5 
hpi the cells were fixed in 3% PFA, autofluorescence was quenched by 
immersion in 50 mM NH4Cl for 15 minutes and the cells were permeabilized 
with 0.1% Triton-X 100 for 2 minutes followed by a 10 minute block in 10% 
human serum in PBS. Cells were immunostained with a gD monoclonal 
antibody and ICP8 antibody. Green: gD, blue: ICP8, red: DN-myoVa or mRED 
control.
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but containing the exon-encoded portion of the myoVa tail domain and the C 
terminal cargo-binding domain, we have now shown that myoVa plays a role in 
exocytosis of HSV virions and glycoproteins in two different epithelial cell lines 
(specifically HEp-2 and HeLa cells). 
 HSV alters the conformation of myoVa as indicated by a substantial increase 
in immunostaining with a myoVa-specific polyclonal antibody starting at about 
4 hpi with HSV-1 (figure 1). According to the manufacturer, this antibody 
recognizes an epitope located between amino acids 260-310. Previous work 
has shown that myoVa exists in two conformations, folded or extended (166), 
and that the folded (inactive) conformation is facilitated by an interaction 
between the C-terminal globular tail domain (GTD) and amino acids 117-137 
of the N-terminal motor domain (153). Based on this information, we postulate 
that the epitope between amino acids 260-310 is masked in the non-active 
conformation as in uninfected cells, whereas the myoVa antibody preferentially 
binds to the active (extended) myoVa in infected cells. Thus, the increased 
fluorescence observed in infected cells stained with this antibody suggests 
that myoVa activity is augmented during HSV-1 infection. This activation might 
play to the advantage of the virus inasmuch as substantial transport activity is 
likely required to support virion secretion.  
     In a previous study, treatment of HSV infected cells with BDM (2,3-
butanedione monoxime) decreased secretion of infectivity into the medium by 
20-50-fold and decreased  production of intracellular virus by 2-fold. BDM is a 
potent inhibitor of myosin II, but also affects calcium flux and many other 
proteins (110,161). The current study specifically implicates myoVa in virus 
 70 
 
secretion inasmuch as expression of dominant negative myoVa reduced 
secretion of infectivity up to 4-fold while titration of extracellular plus 
intracellular infectivity revealed slightly elevated levels. This observation 
indicates that myoVa is involved in transporting infectious virions to the 
extracellular space, whereas earlier steps in the virion assembly pathway in 
which infectious virus is generated do not require myoVa. A role in the final 
egress step of the virion egress pathway is consistent with myoVa’s role in the 
final exocytic step allowing transport of melanosomes (174) and secretory 
granules (130) into the extracellular space.  
     To address the effects of alternative splicing, we used two DN-myoVa 
constructs. The MCLT (melanocyte long tail) construct contained exons D and 
F but lacked exon B, whereas the brain long tail (BRLT) construct contained 
exon B, but not D or F. Because both constructs affected virion secretion 
similarly, we conclude that regions of myoVa required for interaction with 
Rab27a (encoded by exon F) (174), dynein light chain 2 (encoded by exon B) 
(64,165), and Rab10 (encoded by exon D) (127) were dispensable for the 
dominant negative effects. Thus, these effectors were either not involved in 
myoVa-dependent virion secretion or their involvement was redundant.   
It was of interest to us that glycoprotein surface expression at the cell surface 
was significantly (p < 0.05) reduced by the expression of DN myoVa isoforms, 
suggesting that vesicles bearing viral glycoproteins also utilize myoVa to 
facilitate their transport to the plasma membrane. This suggests that the final 
step of virion transport is functionally similar to that of glycoprotein transport to 
the cell surface, at least in the cell types tested. The observation that the 
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dominant negative proteins colocalized with TGN markers suggest that myoVa 
primarily mediates transport from the TGN to the plasma membrane. This 
makes sense in light of the fact that HSV virions are known to transit near or 
through the TGN on their way to the extracellular space (158).  
     We also noted substantial amounts of myoVa in the nuclei of infected cells, 
especially at late times after infection (figure 3.1). MyoVa in the nucleus has 
also been observed in cells infected with pseudorabies virus, a herpesvirus of 
swine (41). While it is possible that myoVa plays a role in active intranuclear 
movement of capsids (43), the production of substantial intracellular infectivity 
in cells expressing the DN-myoVa suggests very minor or no effects on 
transport before the final secretion step when virions are released from the 
plasma membrane. 
     The current work supports a model in which myoVa is activated during 
HSV-1 infection to enhance the transport of secretory vesicles bearing virions 
and viral glycoproteins past cortical actin to eventually fuse with the plasma 
membrane. The study does not rule out roles for other nonmuscle myosins 
and does not exclude other roles for myoVa in the final secretion step. For 
example, the observation that myosin IIa plays a role in stabilizing the fusion 
pore that links the interior of the secretory vesicle to the extracellular space 
(105) would conceivably also enhance virion secretion. From a heuristic 
standpoint, defining the roles of nonmuscle myosins in virion secretion is 
expected to be a useful approach to study how these proteins perform their 
functions in uninfected as well as infected cells. 
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Abstract 
     Previous results suggested that the UL31 gene of herpes simplex virus 1 
(HSV-1) is required for envelopment of nucleocapsids at the inner nuclear 
membrane, and optimal viral DNA synthesis and DNA packaging. In the 
current study, viral gene expression and NFκB and c-Jun N-terminal kinase 
(JNK) activation of a herpes simplex virus mutant lacking the UL31 gene, 
designated ΔUL31, and its genetic repair, designated ΔUL31-R, were studied 
in various cell lines. In Hep2 and Vero cells infected with ΔUL31, expression of 
the immediate early protein ICP4, early protein ICP8, and late protein 
glycoprotein C (gC) were delayed significantly. In Hep2 cells, expression of 
these proteins failed to reach levels seen in cells infected with ΔUL31-R or wild 
type HSV-1(F) even after 18 hours. The defect in protein accumulation 
correlated with poor or no activation of NFκB and JNK upon infection with 
ΔUL31 compared to wild type virus infection. The protein expression defects of 
the UL31 deletion mutant were not explainable by a failure to enter non-
permissive cells, and were not complemented in an ICP27 expressing cell line. 
These data suggest that pUL31 facilitates initiation of infection and/or 
accelerates the onset of viral gene expression in a manner correlated with 
NFκB activation and independent of the transactivator ICP27. The effects on 
very early events in expression are surprising in light of the fact that UL31 is 
designated as a late gene and pUL31 is not a virion component. We show 
herein that while most pUL31 is expressed late in infection, low levels of pUL31 
are detectable as early as 2 hours post infection consistent with an early role 
in HSV-1 infection. 
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 Introduction 
     The herpes simplex virus type 1 (HSV-1) virion, like that of all 
herpesviruses, consists of an envelope surrounding an icosahedral capsid 
shell which contains a double-stranded linear DNA genome. Between the 
proteinaceous capsid and lipid envelope lies an assemblage of more than 20 
viral proteins termed the tegument. Upon entry, some tegument proteins are 
released into the cytosol to help prime the cell for infection. For example, the 
virion host shut off (vhs) protein degrades mRNA to favor viral gene 
expression (78,119) and VP16 (viral protein 16, also designated as α-TIF) 
redirects host transactivators to viral promoters (76,117). Once the virus has 
entered the cell, the cytoplasmic DNA-containing capsid traffics towards the 
host nucleus using the microtubule motor dynein (144). Upon engaging a 
nuclear pore the HSV-1 genome exits the capsid and enters the nucleoplasm 
(6,154). Expression of viral genes is temporally regulated, starting with 
immediate early (α) genes and followed sequentially by early (β), and late 
genes (γ) (67,68). Most α genes encode regulatory proteins. These include, 
ICP4 (infected cell protein 4), that transcriptionally activates other genes, and 
ICP27 which augments viral gene expression at both pre- and post-
transcriptional levels. Gene products from the β class (e.g. ICP8, an essential 
DNA binding protein) are involved in DNA replication, whereas the γ genes 
encode structural proteins like the major capsid protein VP5. Viral DNA 
(vDNA) replication occurs during the transition from β to γ gene expression; 
the γ genes can be further subdivided into γ1 (leaky late) and γ2 (true late). 
This subdivision stems from a dependence on vDNA synthesis. If vDNA 
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replication is blocked, such as with the use of the DNA polymerase inhibitor 
phosphonoacetic acid (PAA), γ1 gene expression is diminished and γ2 gene 
expression is precluded. 
     As the virus enters the cell, cellular signaling events mediate a transition in 
host cell functionality that favors viral propagation. For example, interaction of 
viral glycoprotein D (gD) with a TNF receptor known as herpesvirus entry 
mediator (HVEM, also known as HveA, and TNFRSF14) induces a transient 
activation of NFκB (nuclear factor κB) (140). This induction, lasting 
approximately 2 hours post infection (hpi), is likely stimulated through the 
TRAF (TNF receptor associated factor) signal transduction pathway and is 
dependent on cell type (e.g. the cell must express the appropriate receptor). It 
has also been reported that the tegument protein UL37 has been shown to 
activate NFκB through an interaction with TRAF6 (82). In addition to this 
transient activation of NFκB, there is a second wave of NFκB activation that 
requires de novo HSV-1 gene expression (3). This wave of NFκB activation 
initiates at approximately 6 hpi and has been shown to require the α gene 
product ICP27 (57). NFκB is a transcriptional regulator found in almost every 
cell type and is normally activated in response to cell stress, such as 
inflammation and viral infection [reviewed by (59,60,72)]. While some viruses 
block NFκB activation [for review see (63)] HSV-1 actually requires activation 
of NFκB for efficient infection (113). This requirement has been demonstrated 
by use of dominant negative repressors (2,50,113), knock-out cell lines (50), 
and inhibitory drugs (37). 
     This study focuses on UL31 of HSV-1. Deletion of UL31 decreases viral 
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titers to varying degrees in different cell lines: up to 1000-fold in Vero cells, 
and at least 10-fold in rabbit skin cells (80). pUL31 (the gene product of UL31) 
plays an important role in nuclear egress because viral capsids largely fail to 
bud through the inner nuclear membrane in cells infected with UL31 deletion 
mutants (15,123). A similar phenotype is observed upon deletion of pUL31’s 
interaction partner pUL34 (128), an integral membrane protein localizing to the 
inner nuclear membrane in wild type virus infections. Nuclear rim targeting of 
pUL31 is dependent on expression of pUL34. Without this binding partner, the 
bulk of pUL31 localizes in the nucleoplasm (123). Both UL31 and UL34 are also 
required for alteration of the nuclear lamina (122), composed largely of a 
meshwork of intermediate filaments lining the inner surface of the inner 
nuclear membrane. The nuclear lamina is required for maintaining the 
structure of the nucleus and its pUL31/pUL34-dependent perforation during 
HSV infection is believed to promote access of nucleocapsids to the inner 
nuclear membrane for envelopment. Both pUL34 and pUL31 are incorporated 
into the virion during budding through the inner nuclear membrane into the 
perinuclear space. The envelope of this perinuclear virion is lost upon fusion 
with the outer nuclear membrane as the capsid enters the cytosol; thus, pUL31 
is not a component of the final extracellular virion (44,83,124). Deletion of 
UL31 also diminishes vDNA replication and packaging (15). 
     In the current study, UL31 expression was found to be required for efficient 
NFκB activation and optimal viral protein expression. The latter observation 
may be related to pUL31’s effects on DNA packaging that require late viral 
gene products. The effects on gene expression were shown to be independent 
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of pUL31’s interaction partner pUL34. Although UL31 has been designated as a 
true late gene based on sensitivity of its mRNA to 1-β-D-
arabinofuranosylthymine (65), we have found that pUL31 is detectable at low 
levels as early as 2 hours post infection. This observation suggests that pUL31 
made de novo accounts for its effects on viral protein expression.  
 
 
Materials and Methods 
Viruses and Cells 
     Wild type HSV-1 strain F [HSV-1(F)], ΔUL31 and ΔUL31-R were provided 
by Bernard Roizman and have been described previously (15,35). ΔUL34 was 
provided by Richard Roller and has been described previously (128). d27-1, 
the ICP27-null virus and the ICP27 complimenting cell line V27, were provided 
by Stephen Rice and have been described previously (125). Wild type virus 
stocks [HSV-1(F) and ΔUL31-R] were propagated and titered on Vero cell 
monolayers whereas rabbit skin cells engineered to express pUL31 (80) were 
used to propagate and titer the UL31 deletion virus, ΔUL31. The cell lines were 
maintained in growth medium, consisting of Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 125 units/mL penicillin, 0.125 mg/mL 
streptomycin and 10% newborn calf serum. Two different viral stocks of the 
UL31 deletion virus were used in the reported studies. These stocks produced 
at least 1000-fold more viral plaques per ml on monolayers of the 
complementing cell line than on Vero cells. For all experiments, cells were 
overlayed with 199V medium (DMEM supplemented with 1% newborn calf 
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serum) after infection, and monitored for cytopathic effects until harvesting or 
fixation. 
 
Immunoblot Analyses 
     Mock infected and HSV-1(F) infected cells were washed once in PBS then 
lysed in 100 μL of 2X sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) sample buffer  consisting of 100 mM TrisCl [pH 
6.8], 200 mM dithiothreitol, 4% SDS, 20% glycerol, and 0.2% bromophenol 
blue. Lysates were sonicated and boiled for 5 minutes prior to loading. 
Samples were separated on a 10% polyacrylamide gel and transferred to a 
nitrocellulose membrane (31 volts for 3.5 hours at 4°C). The membrane was 
blocked in 5% milk/TBST (1X tris-buffered saline plus 0.1% Tween) for 1 hour 
at room temperature. The following primary antibodies were diluted in 5% BSA 
in TBST as follows: mouse anti-ICP4 (1:1000, Rumbaugh-Goodwin Institute 
for Cancer Research, Plantation, FL), mouse anti-ICP27 (1:5000, Virusys 
Corporation, Sykesville, MD) rabbit anti-ICP8 (1:10000, a gift from Bill 
Ruyechan), mouse anti-gC (1:1000, Rumbaugh-Goodwin Institute for Cancer 
Research, Plantation, FL),  rabbit anti-phospho Jun N-terminal kinase (p-JNK) 
(1:1000, Cell Signaling #4668), rabbit anti-total JNK (1:1000, Cell Signaling 
#9252), rabbit anti-IκBα (1:1000, Cell Signaling #9242), mouse anti-Lamin A/C 
(1:1000, Santa Cruz Biotechnology sc7292). Diluted primary antibodies were 
reacted with blocked membrane for either 1 hour at room temperature or 
overnight at 4°C with gentle agitation. After extensive washing in PBS, bound 
primary antibody was detected by addition of anti-mouse  (1:2000, Santa Cruz 
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Biotechnology) or anti-rabbit (1:2000, Santa Cruz Biotechnology) horseradish 
peroxidase-conjugated secondary antibody diluted in 5% milk/TBST and 
visualized by enhanced chemiluminescence (Pierce) followed by exposure to 
X-ray film (Pierce). Image J was used for densitometry. 
 
Immunofluorescence  
     Hep2 cells seeded on coverslips in a 12-well dish were either mock 
infected or infected with 10.0 PFU per cell of HSV-1(F), Δ31 or Δ31-R and 
fixed every hour between 1 and 10 hours post infection by washing cells once 
with phosphate buffered saline (PBS) and treating with 3% paraformaldehyde 
(PFA) for 15 minutes at room temperature. The fixed cells were stained with 
Hoechst dye (2 μg/mL in PBS, Invitrogen) for 15 minutes followed by 
immersion in 50 mM NH4Cl for 15 minutes to quench autofluorescence. The 
cells were permeabilized with 0.1% Triton-X 100 for 2 minutes followed by a 
10 minute block in 10% human serum in PBS. Mouse anti-ICP4 (Rumbaugh-
Goodwin Institute for Cancer Research, Plantation, FL) primary antibodies 
were diluted 1:100 in 1% bovine serum albumin (BSA) in PBS, and incubated 
with the fixed cells for 30 minutes in a humidity chamber held at room 
temperature. After washing 3 times in excess PBS, the cells were reacted for 
30 minutes in a humidity chamber with secondary antibodies FITC-conjugated 
anti-mouse IgG (Jackson Laboratories) diluted 1:100 in 1% BSA/PBS. The 
coverslips were then washed 3 times in PBS and dipped in ddH20 before 
mounting on glass slides with mowiol plus 2.5% DABCO to prevent 
photobleaching. All digital images were taken using a Zeiss Axio Imager.M1 
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fluorescence microscope and were processed with Adobe Photoshop 
software. 
 
Drug Treatments 
     In some experiments, Hep2 cells in a 6-well dish were pre-treated with 10 
μM cycloheximide (CHX) for 1 hour at 37°C/5% CO2 or left untreated. After 1 
hour, cells were washed with versene (PBS plus 0.5 μM EDTA 
[(ethylenedinitrilo)tetraacedic acid]) and infected with wild type HSV-1(F) at an 
MOI of 10 PFU/cell or mock infected. 10 μM CHX was included with the added 
virus for the appropriate wells and the cells were rocked slowly for 1 hour at 
37°C to allow for viral attachment and entry. After the 1 hour incubation, the 
virus or mock overlay was removed, the cells were washed with versene, and 
fresh 199V was added back to the cells (containing 10 μM CHX where 
appropriate). At time zero the cells were returned to the 37°C/5% CO2 
incubator until collected. 
     For experiments using phosphonoacetic acid (PAA), Hep2 cells in a 6-well 
dish were infected with HSV-1(F) at an MOI of 10 PFU/cell or mock infected. 
At the start of infection, 200 μg/mL PAA was added to the appropriate well. 
Cells were washed 12 hours later and total cell lysates were collected. For all 
drug treatment experiments, total cell lysates were collected as described 
above under “immunoblot analyses”. 
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Results 
Infections with ΔUL31 but not ΔUL34 are delayed for α, β and γ gene 
expression. 
     It has been previously reported that ΔUL31 infections result in decreased 
viral DNA accumulation, cleavage and packaging (15). The current studies 
were initiated to determine how pUL31 might contribute to these activities, with 
the hypothesis that UL31 might augment viral gene expression. Because 
pUL31 interacts with pUL34, we included a ΔUL34 virus in the experiment to 
determine if any detected phenotype was dependent upon the pUL31-pUL34 
interaction. Hep2 cells were mock infected or infected with wild type HSV-1(F), 
ΔUL31 or ΔUL34 viruses at an MOI of 10 PFU per cell. At 4 and 18 hours post 
infection (hpi), total cell lysates were collected and proteins separated by SDS-
PAGE as described in the materials and methods section. The results are 
shown in figure 4.1. For this and subsequent immunoblots, quantification was 
done using Image J. Similar results were noted in Hep2 cells infected with the 
UL31 deletion virus at up to 50 PFU per cell (data not shown). 
     Surprisingly, immunoblotting (figure 4.1) showed that essentially no ICP4 
(an α gene product) or ICP8 (a β gene product) accumulated to detectable 
levels by 4 hpi in cells infected with the ΔUL31 virus, whereas both proteins 
were detected at this time point in cells infected with either the wild type HSV-
1(F) or ΔUL34 viruses. At 4 hpi, ICP4 and ICP8 protein levels in the ΔUL31 
infection were only 3% and 5%, respectively, of those seen from the infection  
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Figure 4.1 Delayed protein expression in Hep2 cells infected with ΔUL31 
but not ΔUL34 viruses. Hep2 cells were infected with 10 PFU per cell of 
HSV-1(F), ΔUL31, ΔUL34 or were mock infected. Total cell lysates were 
collected at 4 and 18 hpi. Proteins were denatured and separated by SDS-
PAGE, transferred to a nitrocellulose membrane and reacted with antibodies 
against ICP4, ICP8, gC, p-JNK, total JNK, IκBα or Lamin A/C, which was used 
as a loading control.  Bound antibodies were revealed by reaction with 
appropriately conjugated antibodies followed by chemiluminescence and 
exposure to X-ray film as described in materials and methods.
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with wild type virus. Although both ICP4 and ICP8 protein levels increased in 
the lysate of the ΔUL31 infection by 18 hpi, the levels were only 55% and 41% 
of levels in HSV-1(F) infection. Protein levels of the γ2 gene product 
glycoprotein C (gC) in the ΔUL31 infection accumulated to only 34% of gC 
from infection with the wild type HSV-1(F). For all cases, infections with the 
ΔUL34 virus resulted in protein levels similar to or higher than wild type 
infection. We conclude that UL31 is necessary for optimal expression of at 
least one member of each kinetic class of viral protein. 
     Because it has been shown previously that inhibition of NFκB activity by the 
drug resveratrol resulted in reduced levels of several α gene mRNAs and 
undetectable levels of gC mRNA (37) we hypothesized that pUL31 might 
augment viral protein expression by ensuring activation of the transcriptional 
regulator NFκB. To test this possibility, we probed immunoblots of total 
infected cell proteins with antibody to IκBα, the NFκB inhibitor. IκBα binds 
NFκB in the cytosol inhibiting its translocation into the nucleus, thus 
maintaining a pool of inactive (transcriptionally incompetent) NFκB (61,72). 
Upon NFκB activation, IκBα is phosphorylated, polyubiquitinated and finally 
degraded. Normally in HSV-1 infections, NFκB activation is observed as early 
as 6 hpi, and this activation can be measured by the concomitant absence of 
the NFκB repressor, IκBα (57). As shown in figure 4.1, IκBα accumulated to 
similar levels at 4 hpi in all samples. At 18 hpi, IκBα protein levels from HSV-
1(F) and ΔUL34 infected cells were 8% and 2% of mock infected cells whereas 
ΔUL31 infected cell lysates contained protein levels of IκBα at 85% of mock. 
These data indicate that UL31 plays a role in ensuring elimination of IκBα in 
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infected cells, and thus activation of NFκB. 
     We also examined relative levels of activated (phosphorylated) c-Jun N-
terminal kinase (p-JNK) and found that at 18 hpi the ΔUL31 virus induced 
levels of p-JNK amounted to only 28% of the level detected from the wild type 
HSV-1(F) infection. In contrast, levels of total JNK were similar in all lanes. 
Taken together, the results indicate that in addition to a viral protein 
expression deficiency, the ΔUL31 virus exhibits deficiencies in NFκB and JNK 
activation that are normally seen during HSV-1 infection.  
 
NFκB and JNK activation are down-regulated in ΔUL31 infections of 
different cell types. 
     To determine if NFκB and JNK activation seen in the UL31 deletion virus 
(ΔUL31) infected Hep2 cells (figure 4.1) occurred in other cell types, rabbit skin 
cells (RSC), Vero, HeLa and Hep2 cells, as well as the ΔUL31 complementing 
cell line, clone 7 (an RSC derivative) were mock infected or infected with the 
ΔUL31, HSV-1(F) or ΔUL31-R (repair) viruses. All cell types were infected at 
an MOI of 10 PFU per cell and total cell lysates were collected at 4, 8, 12 and 
18 hpi as described in materials and methods. Equal amounts of proteins from 
each sample at each time point were separated by SDS-PAGE, transferred to 
nitrocellulose membranes, and were reacted with antibody for IκBα (the NFκB 
repressor), total JNK and phosphorylated (activated) JNK (p-JNK) as 
described in materials and methods. Sample loading was assessed by probing 
with an antibody directed against lamin A/C. Although the amounts loaded in 
each lane were consistent within samples from a given cell line, they varied 
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somewhat between cell lines. Nevertheless, the consistency of loading 
between samples from each cell type enabled comparisons of protein 
expression by the different viruses in each cell type examined.  
     Overall, the results indicated a positive correlation between defects in 
protein synthesis in ΔUL31 infections (as shown in figure 4.1), and both 
decreased JNK and NFκB activation in the various cell lines (as shown in 
figure 4.2) as follows.  
     In the non-permissive Hep2 and HeLa cell lines, IκBα levels were similar 
upon infection with all viruses at 4 hpi, whereas at later time points IκBα was 
down regulated to 36% and 34% of mock infected cells in HSV-1(F) and 
ΔUL31-R, respectively. However, in cells infected with ΔUL31 IκBα was down 
regulated to only 78% of mock levels. The differences were accentuated at 18 
hpi when IκBα was down regulated to 15% and 7% of mock in HSV-1(F) and 
ΔUL31-R, respectively, but down regulated to only 76% of mock in the ΔUL31 
infection.  
     In HeLa cells, activated JNK was first detected at 8 hpi in cells infected with 
HSV-1(F) and ΔUL31-R, but in cells infected with ΔUL31 the p-JNK level was 
only 8% of that in cells infected with ΔUL31-R. Even at 18 hpi, the p-JNK level 
in ΔUL31 infected cells was only 15% of that in the ΔUL31-R infection. 
Although activated JNK was never abundant in Hep2 cells, it was first detected 
at 8 hpi with the wild type virus. p-JNK levels were significantly lower at later 
time points (8%, 3% and 0.4% of p-JNK levels in cells infected with ΔUL31-R  
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Figure 4.2 NFκB and JNK activation are down-regulated in ΔUL31 
infections of different cell types. Rabbit skin cells (RSC), clone 7 (#7), Vero, 
Hep2, or HeLa cells were infected with 10.0 PFU per cell of HSV-1(F), ΔUL31, 
ΔUL31-R, or were mock infected. Clone 7 is derived from RSC’s and partially 
complements replication of the UL31 deletion virus. Total cell lysates were 
collected at 4, 8, 12 and 18 hpi. Proteins were separated by SDS-PAGE, 
transferred to a nitrocellulose membrane and reacted with antibodies against 
p-JNK, total JNK, and IκBα.  Antibody to Lamin A/C was used as a loading 
control.  Bound antibodies were revealed by reaction with appropriately 
conjugated antibodies followed by chemiluminescence and exposure to X-ray 
film as described in materials and methods. 
 88 
 
 
 89 
 
at 8, 12 and 18 hpi, respectively). 
     Vero cells, unlike Hep2 and HeLa cells, exhibited easily detectable 
phosphorylated JNK as early as 4 hpi, although levels in cells infected with 
ΔUL31 were 46% of the level observed upon infection with ΔUL31-R. The 
differences in activated JNK levels decreased over time such that by 18 hpi, 
the level of JNK activation in Vero cells infected with ΔUL31 was 92% of that in 
Vero cells infected with ΔUL31-R. In general, IκBα levels in Vero cells were 
inversely correlated with those of activated JNK. Although the IκBα level was 
higher by 8 hpi with ΔUL31 (22% of mock) than upon infection with the repair 
virus (0.9% of mock), differences among the different viral infections were 
negligible by 12 hpi (58% for F, 61% for ΔUL31 and 47% for ΔUL31-R relative 
to mock). We conclude that Vero cells infected with ΔUL31 are more 
permissive with respect to NFκB and JNK activation than either Hep2 or HeLa 
cells infected with this virus.  
     Immunoblot signals of IκBα were not as strong in RSC’s as in the other cell 
lines examined. Nevertheless, this cell line contained more IκBα when mock 
infected or infected with ΔUL31 compared to levels in cells infected with the 
wild type HSV-1(F) and ΔUL31-R. Compared to mock IκBα levels in HSV-1(F), 
ΔUL31, and ΔUL31-R were 19%, 167%, and 21%, respectively. The 
differences in IκBα levels in the different virus infections were largely 
eliminated by 12 hpi, as percentage of detectable IκBα relative to mock were 
3%, 16% and 2% for HSV-1(F), ΔUL31, and ΔUL31-R, respectively. Very little 
activated JNK (p-JNK) was detected in RSC’s at any time point. Thus, rabbit 
skin cells were more permissive with respect to NFκB and JNK activation in 
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the context of ΔUL31 than either Hep2 or HeLa cells.  
     In clone 7 cells, which partially rescue the UL31 deletion virus (80), less 
activated JNK and more IκBα were observed after infection with ΔUL31 than 
with the other viruses. Specifically, the IκBα levels were only 11% relative to 
mock in infections with the ΔUL31-R virus, but 63% with ΔUL31 at 8 hpi. At 4 
and 8 hpi, p-JNK levels in cells infected by ΔUL31 were 16% and 45%, 
respectively, compared to levels in infections with the repair virus. Relevant to 
this observation, we have noted a delay in viral protein expression in clone 7 
cells infected with ΔUL31 (data not shown) and an inability of these cells to 
restore its replication to the level seen upon infection with ΔUL31-R (80). Thus, 
the incomplete rescue of ΔUL31 replication and protein expression in this cell 
line correlates with poor JNK and NFκB activation.   
 
ICP27 provided in trans does not rescue the observed defects of ΔUL31 
infected Vero cells. 
     Previous reports suggested that loss of ICP27 could produce similar 
defects to those we have observed in characterization of the UL31 deletion 
mutant (57,58). We therefore examined NFκB and JNK activation, and gC 
expression in an ICP27 expressing cell line (V27) infected with ΔUL31, HSV-
1(F), ΔUL31-R and d27-1 (ICP27 null) viruses. Vero cells were used as a 
control because V27 is derived from this cell type (125). The results are 
presented in figure 4.3. 
     In both Vero and V27 cells, JNK activation was decreased in the ΔUL31 
infection relative to wild type HSV-1(F) levels. The presence of ICP27 provided 
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in trans (V27 cells) partially rescued JNK activation in both the ΔUL31 and 
ICP27-null virus (d27-1). Specifically, p-JNK protein levels in the ΔUL31 and 
d27-1 infections increased from 15% and 31% (respectively) of wild type levels 
at 4 hpi to 50% and 67% (respectively) of wild type levels at 8 hpi. In contrast, 
p-JNK protein levels in Vero cells remained at similar levels in cells infected 
with ΔUL31 compared to wild type infection at 4 and 8 hpi (66% and 59% of 
wild type levels, respectively).  
     ICP4 expression in ΔUL31 infected Vero and V27 cells was dramatically 
reduced compared to wild type infections in these cell types. At 4 and 8 hpi, 
ICP4 protein levels in the ΔUL31 Vero infections were 0.6% and 54% of wild 
type, respectively. The presence of ICP27 provided in trans failed to rescue 
ICP4 expression for both ΔUL31 and ICP27-null (d27-1) infections by 8 hpi. In 
ΔUL31 and d27-1 infections in V27 cells, ICP4 protein levels were only 17% 
and 8% of wild type infection (respectively) at 4 hpi and increased to only 23% 
and 11% of wild type infection (respectively) at 8 hpi. 
     Lysates from ΔUL31 infected Vero and V27 cells contained readily 
detectable protein levels of IκBα at 8 hpi (70% and 119% of mock, 
respectively), whereas wild type infections resulted in IκBα levels that were 
only 32% and 16% observed in mock infection. This is an indication that NFκB 
was not activated normally in the ΔUL31 infections. ICP27 provided in trans 
was sufficient to rescue NFκB activation in the ICP27-null virus by 8 hpi since 
IκBα protein level from the d27-1 infection was only 10% of mock. 
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Figure 4.3 ICP27 in the V27 cell line does not rescue the protein 
expression deficits of ΔUL31 at early times after infection. Vero or the 
Vero-derived ICP27 expressing cell line V27 were infected with HSV-1(F), 
ΔUL31, ΔUL34, d27-1 or mock infected at an MOI of 10 PFU per cell. Total cell 
lysates were collected at 4 and 8 hpi and the denatured proteins were 
separated by SDS-PAGE, transferred to a nitrocellulose membrane and 
reacted with antibodies against ICP4, ICP27, p-JNK, and IκBα.  Lamin A/C 
was used as a loading control. The order in lanes 1-4 were modified from the 
original blot to match the order of loaded samples run previously. Bound 
antibodies were revealed by reaction with appropriately conjugated antibodies 
followed by chemiluminescence and exposure to X-ray film as described in 
materials and methods. 
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 We conclude that ΔUL31’s defects in protein expression and NFκB and 
activation cannot be complemented in an ICP27 expressing cell line, and JNK 
activation is only partially rescued. This suggests that UL31’s contribution to 
activation of NFκB and JNK is mostly independent of ICP27. 
 
Infection with ΔUL31 leads to delayed expression of ICP4 but not failure 
to initiate infection. 
     One possible explanation of the current results is that the ΔUL31 virus is 
unable to efficiently enter or otherwise infect cells. In this scenario, the 
observed phenotypes might simply reflect a large number of uninfected cells in 
the population. To address this possibility, we infected the restrictive Hep2 cell 
line with the ΔUL31 or ΔUL31-R viruses at a multiplicity of infection (MOI) of 10 
PFU per cell. Cells were fixed at 1, 6 and 10 hpi and stained with antibody to 
ICP4 to visualize infected cells, and Hoechst dye to visualize cellular nuclei. 
The results are presented in figure 4.4A. 
     At all time points examined, nuclei were present throughout the visual field. 
At 1 hpi, no ICP4-specific immunofluorescence was visible in ΔUL31 or ΔUL31-
R infected cells. At 6 hpi many ΔUL31-R infected cells exhibited ICP4-specific 
immunofluorescence, whereas only a few cells infected with ΔUL31 displayed 
such immunostaining. At 10 hpi, many ICP4-positive cells were found 
throughout the ΔUL31-R and ΔUL31 infected cell monolayers. These 
observations are  consistent with the data presented above indicating that 
cells infected with wild type viruses express high levels of ICP4 at early time 
points whereas ICP4 expression in ΔUL31 infected cells starts at very low 
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levels that increase with time post infection. The gradual increase in ICP4 
expressing cells upon infection with the UL31 deletion virus cannot be a 
consequence of cell to cell spread within the culture because (i) this would not 
be expected at 6 hpi and (ii) the UL31 deletion virus cannot exit non-
complementing cells. A quantification of infection efficiency at 6 hpi and 10 hpi 
is shown in figure 4.4B. Student’s T-test demonstrated that the difference in 
the number of ICP4-expressing cells out of total cells was statistically 
significant (p < 0.001) whereas this difference was no longer statistically 
different at 10hpi (p > 0.05). The difference in the 6 and 10 hpi time points in 
ΔUL31 infected cells was also statistically different  (p < 0.01), indicating that a 
significant number of cells transitioned from not expressing ICP4 at detectable 
levels to detectable expression over the course of 4 hours. We conclude that 
the defects in ICP4 expression observed in cells infected with the UL31 
deletion were due to a delay in the onset of expression, rather than a failure of 
the virus to enter and infect a subset of cells. 
 
UL31 expression is detectable early in infection. 
     The effects of pUL31 in early protein expression were seemingly 
incongruous with its sole expression late in infection. To test whether or not 
UL31 is only expressed late in infection, Hep2 cells were treated with 10 μM 
cycloheximide (CHX) or left untreated for 1 hour. The cells were then infected 
with wild type HSV-1 (MOI = 10) or mock infected. For CHX treated cells, the 
CHX was maintained at all steps of infection. Total cell lysates were collected 
at 1, 2, 3 and 5 hours post infection (hpi) and proteins were separated by  
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Figure 4.4 Infection with ΔUL31 leads to delayed expression of ICP4 but 
not failure to initiate infection. (A) Hep2 Cells were infected at an MOI of 10 
PFU per cell of either ΔUL31 or its genetic repair ΔUL31-R and were fixed at 1, 
6 or 10 hpi in PFA, permebilized, and stained with antibody to ICP4 (green) to 
visualize infected cells, and the cells were counterstained with Hoechst dye 
(blue) to visualize cellular nuclei. (B) Quantification of ratio of ICP4-expressing 
cells to total cells infected with ΔUL31-R or ΔUL31 (MOI = 10 PFU per cell) at 6 
and 10 hpi. The Student’s T-test showed a statistically significant difference in 
ICP4 expression in the ΔUL31-R and ΔUL31 infected cells at 6 hpi (p < 0.001, 
noted by *) but not 10 hpi (p > 0.05). The same statistical test showed a 
statistically significant difference in ICP4 expression in ΔUL31 infected cells 
fixed at the 6 and 10 hpi time points (p < 0.01, noted by *).
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SDS-PAGE. Immunoblots were probed with antibody to pUL31, ICP4 and 
lamin A/C (loading control). The results are presented in figure 4.5. 
     The data indicate that UL31 is expressed at detectable levels as early as 2 
hpi. The kinetics of pUL31 expression early in infection correlated with those of 
ICP4 expression whereas at 5 hpi, the amount of pUL31 increased more 
dramatically than those of ICP4. Importantly, little or no protein was visible in 
the CHX-treated lysates, indicating that, as expected, the early detection of 
pUL31 is due to active transcription/translation and was not a consequence of 
its presence within the innoculum. These data indicate that UL31, previously 
thought to be expressed only at late times after infection, has low level 
expression at early times after infection.  
 
UL31 expression late in infection is PAA-sensitive. 
     Since true late genes are sensitive to DNA polymerase inhibitors, we asked 
whether pUL31 expression late in infection was dependent on vDNA synthesis 
[i.e sensitive to the DNA polymerase inhibitor phosphonoacetic acid (PAA)]. To 
test this possibility, Hep2 cells were infected with wild type HSV-1(F) (MOI=10) 
or were mock infected in the presence or absence of 200 μg/mL PAA. At 12 
hours post infection total cell lysates were collected and proteins separated by 
SDS-PAGE. The immunoblot was reacted with antibody to pUL31 or lamin A/C 
as a loading control. The results are presented in figure 4.6. 
     The presence of PAA significantly diminished pUL31 expression in HSV-1 
infected cells. These data are consistent with UL31 expression as a late gene, 
but are not inconsistent with an important role(s) of pUL31 early in infection.  
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Figure 4.5 UL31 expression is detectable early in infection. Hep2 cells 
were pre-treated with 10 μM cycloheximide (CHX) for 1 hour at 37°C/5%CO2 
or left untreated. After the 1 hour treatment, cells were infected with 10 PFU 
per cell of wild type HSV-1(F) or were mock infected. Cells were incubated an 
additional hour at 37°C with gentle agitation to allow for viral attachment and 
entry, then the overlay was replaced with fresh media containing 10 μM CHX 
where appropriate.  Total cell lysates were collected at 1, 2, 3 and 5 hours 
post infection and proteins were separated by SDS-PAGE. The immunoblot 
was reacted with antibody to pUL31, ICP4 or lamin A/C. Bound antibodies 
were revealed by reaction with appropriately conjugated antibodies followed 
by chemiluminescence and exposure to X-ray film as described in materials 
and methods.
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Figure 4.6 UL31 expression is dependent on viral DNA replication. Hep2 
cells were infected with wild type HSV-1(F) (MOI = 10 PFU per cell) or were 
mock infected in the presence or absence of 200 μg/mL phosphonoacetic acid 
(PAA) at the start of infection. At 12 hours post infection (hpi) total cell lysates 
were collected and proteins separated by SDS-PAGE. The immunoblot was 
reacted with antibody to gC, pUL31 or lamin A/C. Bound antibodies were 
revealed by reaction with appropriately conjugated antibodies followed by 
chemiluminescence and exposure to X-ray film as described in materials and 
methods.
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Discussion 
  Besides its well documented role in nuclear egress, the current data argue 
that pUL31 plays a role in optimizing viral protein production and activation of 
JNK and NFκB, especially in Hep2 and HeLa cells. These functions are 
separable kinetically. Specifically, UL31 acts to increase early gene expression 
at times before the activation of JNK and NFκB, which normally occur at 6 
hours post infection with HSV-1.  It is therefore unclear whether pUL31 itself, 
or another viral protein whose optimal expression depends on pUL31, is 
responsible for activation of NFκB and JNK. After 6 hours, however, the failure 
to activate signaling molecules in cells infected with the UL31 null virus can no 
longer be kinetically separated from defects in viral gene expression. 
 The degree to which pUL31 mediates its effects on viral protein accumulation 
varies in different cell lines. For example, the block in NFκB and JNK 
activation is relieved with time in RSC and Vero cells, but less so in Hep2 and 
HeLa cells. The previously noted restriction of UL31 deletion mutant replication  
in Vero cells, and relative permissivity of RSCs (80), is therefore 
experimentally separable from UL31-mediated effects on NFκB and JNK 
activation. We have also shown that the defects of the UL31 deletion virus 
cannot be rescued by expression of ICP27 in trans, suggesting that pUL31 
performs different functions than this potent viral regulator. Perhaps most 
importantly, the effect of pUL31 on viral protein accumulation can be 
distinguished from its interaction with pUL34, because protein expression 
defects were not observed in cells infected with a UL34 deletion virus as noted 
previously (128). It follows that because the nuclear lamina is not perforated, 
 102 
 
nor do particles bud from the nuclear membrane in cells infected with the UL34 
deletion virus (122,123,128), that the function of pUL31 on protein expression 
is independent of its roles in nuclear egress or effects on the nuclear lamina. 
While we do not know the mechanism by which pUL31 augments viral protein 
expression and cell signaling, its localization in the nucleoplasm must be 
sufficient to mediate these functions because pUL31 is located solely in the 
nucleoplasm of cells with the UL34 deletion virus (123). Such localization 
suggests possible roles in transcription, stability or export of mRNAs and 
studies are currently underway to distinguish between these possibilities. It is 
possible that the presence of pUL31 early in infection is important for blocking 
nascent expression of the NFκB repressor, IκBα, during the second wave of 
NFκB activation (3). How and which of these putative activities are 
consequential to (or dependent on) UL31-dependent JNK and NFκB activation 
will require further studies. It is logical that incomplete blocks in these 
processes could be relieved by prolonged incubation, just as we see in cells 
infected with the UL31 deletion virus. 
 
Acknowledgements 
     We thank Bill Ruyechan for the ICP8 antibody, Bernard Roizman for the 
ΔUL31 and ΔUL31-R viruses, Richard Roller for the ΔUL34 virus and Stephen 
Rice for the V27 cell line and the d27-1 virus. These studies were supported 
by grants R01 AI52341 and T32 AI007618 from the National Institutes of 
Health. 
  
 103 
 
CHAPTER V 
UL31 of herpes simplex virus 1 is necessary for optimal expression of 
viral gene products and host shut off 
 
Kari L. Roberts and Joel D. Baines, Department of Microbiology and 
Immunology, Cornell University, Ithaca, NY 14853. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 104 
 
Abstract 
     Previous results suggested that the UL31 gene of herpes simplex virus 1 
(HSV-1) is required for envelopment of nucleocapsids at the inner nuclear 
membrane, and optimal viral DNA synthesis and DNA packaging. In the 
current study, viral gene expression of a herpes simplex virus mutant lacking 
the UL31 gene, designated ΔUL31, and its genetic repair, designated ΔUL31-R, 
were studied in various cell lines. After propagation in pUL31 complementing 
cell lines, expression of the immediate early protein ICP4, early protein ICP8, 
and late protein glycoprotein C (gC) were delayed significantly in all cell types 
in the next round of infection with ΔUL31. In some cell types, expression of 
these proteins failed to eventually reach levels seen in cells infected with 
ΔUL31-R or wild type HSV-1(F). These data suggest UL31 facilitates initiation 
of infection and/or accelerates the onset of viral gene expression. The effects 
on very early events in expression suggest that it plays important (but perhaps 
indirect) roles later in the assembly pathway.  
 
Introduction 
     Herpes simplex virus type 1 (HSV-1) is a large, enveloped DNA virus that 
expresses more than 70 genes during the course of an infection (88). Viral 
gene expression is organized into three distinct kinetic classes of genes 
designated immediate early (α), early (β) and late (γ) (67,68). The late genes 
can be further categorized as leaky late (γ1) and true late (γ2), where γ1 gene 
expression is augmented by viral DNA replication and γ2 gene expression 
completely depends upon it. The β and γ genes encode the proteins 
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necessary for viral replication, including the production of novel viral DNA and 
virion structural components (e.g. capsid proteins), respectively.   
     Upon entry, the tegument disperses into the cytoplasm and interacts with 
various host factors to help establish conditions conducive to HSV-1 protein 
expression. Functions known to contribute include (i) shut off of host protein 
synthesis by the UL41 gene product vhs, which degrades mRNA to favor viral 
gene expression (78,119), and (ii) preferential transactivation of viral genes at 
the expense of host genes through the redirection of host transactivators to 
viral promoters by the UL48 gene product VP16 (α-TIF) (76,117).   
     Several immediate early proteins also act to favor the viral transcription 
program over that of the host. For example, ICP4 is a major transactivator of 
some viral genes whereas the α gene product ICP27 augments HSV-1 gene 
expression at both pre- and post-transcriptional levels. ICP27 interacts with 
RNA polymerase II to help initiate transcription (176) and recruits the 
polymerase to viral replication sites within the nucleus (26). Once these viral 
transcripts are produced, ICP27 further assists expression by binding viral 
mRNA (23,135) and helping to mediate its export to the cytoplasm 
(75,135,145). Additionally, ICP27 has been shown to be necessary for the 
activation of NFκB during HSV-1 infection (57).  
     NFκB, a transcription regulator found in almost every cell type, is normally 
activated by cell stress such as that induced during inflammation and viral 
infection (59,60,72). In some viral infections the NFκB pathway is blocked by 
the invading viruses; however, HSV-1 is known to activate NFκB (48,113,129).  
     β gene expression is required for viral DNA replication. ICP8 is a long 
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established marker of this stage of infection and helps create the viral DNA 
replication compartment within the nucleus of the infected cell (26). While viral 
DNA synthesis augments protein expression of γ1 genes, it is absolutely 
required for protein expression of γ2 genes. During the γ phase of infection, a 
subset of structural proteins assemble into capsids and genomic viral DNA is 
inserted. The gene product for UL31 [pUL31, classified as γ2 based on 
sensitivity of its mRNA to 1-β-D-arabinofuranosylthymine (13)] localizes to the 
nucleus where it interacts with pUL34 (γ2) at the nuclear rim. This interaction is 
critical for envelopment of nucleocapsids at the inner nuclear membrane (28) 
and there is also some evidence that pUL31 is involved in viral DNA packaging 
(2). 
     In the current study, we observed a novel defect during infection with a 
UL31-null virus (ΔUL31) inasmuch as expression of the α protein ICP4, β 
protein ICP8, and γ gene glycoprotein C (gC) were delayed in several cell 
types infected with the UL31 deletion mutant. These effects were not evident in 
infections with a mutant HSV-1 lacking the gene for pUL34 (the binding partner 
of pUL31) and correlated with poor activation of the transcription regulator 
NFκB as described in chapter IV. Despite the fact that pUL31 is not a virion 
component, the data suggests that its well documented roles in viral assembly 
play important roles in subsequent initiation of viral infection.  
  
Materials and Methods 
Viruses and Cells 
     Wild type HSV-1 strain F [HSV-1(F)], ΔUL31 and ΔUL31-R were kindly 
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provided by Bernard Roizman and have been described previously (15,35). 
Virus stocks were propagated and titered on Vero cell monolayers [HSV-1(F)] 
or rabbit skin cells engineered to express pUL31 (80). The cell lines were 
maintained in growth medium, consisting of Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 125 units/mL penicillin, 0.125 mg/mL 
streptomycin and 10% newborn calf serum. Two different viral stocks of the 
UL31 deletion virus were used in the reported studies. These stocks were 
titered on both Vero cells and the UL31 expressing cell line (80), and produced 
at least 1000-fold more viral plaques per mL on monolayers of the 
complementing cell line than on Vero cells. For all experiments, cells were 
overlayed with 199V medium (DMEM supplemented with 1% newborn calf 
serum) after infection, and monitored for cytopathic effects until harvesting or 
fixation.   
 
Immunoblot Analyses 
     Mock infected and HSV-1(F) infected cells were washed once in PBS then 
lysed in 100 μL of 2X sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) sample buffer (100 mM TrisCl [pH 6.8], 200 mM 
dithiothreitol, 4% SDS, 20% glycerol, 0.2% bromophenol blue). Lysates were 
sonicated and boiled for 5 minutes prior to loading. Samples were separated 
on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane (30 
volts for 3.5 hours at 4°C). The membrane was blocked in 5% milk/TBST (1X 
tris-buffered saline plus 0.1% Tween) for 1 hour at room temperature. The 
following primary antibodies were diluted in 5% BSA in TBST as follows: 
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mouse anti-ICP4 (1:1000, Rumbaugh-Goodwin Institute for Cancer Research, 
Plantation, FL), rabbit anti-ICP8 (1:10000, a kind gift from Bill Ruyechan), 
mouse anti-gC (1:1000, Rumbaugh-Goodwin Institute for Cancer Research, 
Plantation, FL), mouse anti-Lamin A/C (1:1000, Santa Cruz Biotechnology 
sc7292). Diluted primary antibodies were reacted with blocked membrane for 
either 1 hour at room temperature or overnight at 4°C with gentile agitation. 
After extensive washing in PBS, bound primary antibody was detected by 
addition of anti-mouse (1:2000, Santa Cruz Biotechnology) or anti-rabbit 
(1:2000, Santa Cruz Biotechnology) horseradish peroxidase-conjugated 
secondary antibody diluted in 5% milk/TBST and visualized by enhanced 
chemiluminescence (Pierce) followed by exposure to X-ray film (Pierce).  
 
35S Met/Cys Metabolic Labeling 
     Hep2 cells were seeded into 6-well dishes and mock infected or infected 
with 20.0 PFU per cell of HSV-1(F), 20.0 PFU per cell of Δ31-R or 50.0 PFU 
per cell of Δ31 and held at 4°C with gentile agitation for 1 hour to allow for viral 
attachment. Next, cells were washed in PBS and incubated with DMEM 
lacking L-glutamine, methionine, and cysteine (starvation medium) for 30 
minutes at 37°C. To label proteins, cells were overlayed with starvation 
medium supplemented with 20 μCi 35S methionine per well for three hours at 
0-3, 3-6, 6-9, 9-12 and 12-15 hours post infection. After the three hour labeling 
periods, cells were washed in PBS and collected in 150 μL 2X SDS sample 
buffer, sonicated and stored at -80°C. After all time points were collected, 
lysates were boiled for 5 minutes before loading. Radiolabeled lysates were 
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separated on a 12% polyacrylamide gel and transferred to a nitrocellulose 
membrane. Labeled proteins were visualized by autoradiography on X-ray film 
(Pierce). 
 
Results 
Viral protein accumulation and host shut-off are delayed in ΔUL31 
infections. 
     To further document a role for pUL31 in augmenting viral gene expression, 
Hep2 cells were infected with ΔUL31, wild type HSV-1(F) or ΔUL31-R (a virus 
derived from the UL31 deletion virus but bearing a restored UL31). The 
multiplicity of infection (MOI) for wild type (F) and ΔUL31-R was 20 PFU/cell, 
while the MOI for ΔUL31 was 50 PFU per cell to ensure each cell was infected. 
At various times after infection, proteins were radiolabeled for 3 hours with 
[35S] methionine and cystine and cellular lysates were prepared after each 
labeling interval over 18 hours. Proteins were then denatured, 
electrophoretically separated on an SDS polyacrylamide gel, transferred to a 
nitrocellulose membrane and the membrane was exposed to X-ray film 
(Pierce) to visualize proteins. The results are presented in figure 5.1. 
     Expression of many prominent early viral proteins was delayed in cells 
infected with ΔUL31. Some proteins in lysates of cells infected with HSV-1(F) 
and ΔUL31-R (in bands denoted with •, † or ‡) likely represented immediate 
early or early gene products inasmuch as they were readily detectable by 0-3 
hours with continued high expression up to 6 hours after infection (lanes 2-3 
and 14-15, respectively). These same proteins were not expressed in ΔUL31 
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until 3-6 hpi (lane 9) and the expression level was diminished compared to the 
wild type controls (lanes 2-3; 14-15). Bands denoted with • and ‡ did not peak 
in the ΔUL31 infection until the 9-12 hpi time point (lane 11) and never reached 
corresponding levels obtained in the HSV-1(F) and ΔUL31-R infected cell 
lysates (lanes 3 and 15, respectively). In addition to the delay and deficiency in 
viral protein synthesis by the ΔUL31 virus, we also noted a delay in host shut 
off inasmuch as some bands present in mock infected cells (one is 
represented by *) were detected for longer amounts of time in cells infected 
with ΔUL31 compared to levels seen in HSV-1(F) and ΔUL31-R infections 
[compare lane 1 (mock) to lanes 2-3 and 14-15 (F and ΔUL31-R, respectively) 
and lanes 8-11 (ΔUL31)].  
 
Effects of UL31 on expression of viral proteins in different cell types 
     To determine if protein accumulation of viral gene products was delayed in 
other cell types, rabbit skin cells (RSC), Vero, HeLa and Hep2 cells, as well as 
the ΔUL31 complementing cell line, clone #7 (an RSC derivative) were mock 
infected or were infected with the ΔUL31, HSV-1(F) or ΔUL31-R viruses. Equal 
amounts of proteins from each sample at each time point were separated by 
SDS-PAGE and transferred to nitrocellulose membranes, reacted with relevant 
antibodies as described in materials and methods. The results are shown in 
figure 5.2. 
     Sample loading was assessed by probing with an antibody directed against 
lamin A/C. Although the amounts loaded in each lane were consistent within 
samples from a given cell line, they varied somewhat between cell lines. The  
 111 
 
 
 
 
 
 
 
 
Figure 5.1 35S metabolic labeling of total proteins produced during HSV-1 
infection. Hep2 were mock infected or infected with 20.0 PFU per cell of HSV-
1(F), 20.0 PFU per cell of Δ31-R or 50.0 PFU per cell of Δ31. Cells were 
overlayed with starvation medium supplemented with 20 μCi 35S methionine 
per well for three hours at 0-3, 3-6, 6-9, 9-12 and 12-15 hours post infection. 
Radiolabeled lysates were separated on a 12% polyacrylamide gel, 
transferred to a nitrocellulose membrane and visualized by autoradiography.
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Figure 5.2 Representative viral proteins from each kinetic class are 
down-regulated in ΔUL31 infections of different cell types.  
Cells were infected with HSV-1(F), ΔUL31, ΔUL31-R or mock infected at an 
MOI of 10 PFU per cell. Lamin A/C was used as a loading control. Bound 
antibodies were revealed by reaction with appropriately conjugated antibodies 
followed by chemiluminescence and exposure to X-ray film as described in 
materials and methods. 
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consistency of loading between samples from each cell type enabled 
comparisons of protein expression by the different viruses in each cell type 
examined.   
          Expression of immediate early and early proteins was delayed in all cell 
types infected with ΔUL31. Expression of the γ2 gene product glycoprotein C 
(gC) was delayed slightly in clone #7, RSC and Vero cells at 8 hpi but reached 
wild type levels by 12 hpi.       
     Both Hep2 and HeLa cells were more restrictive to protein expression by 
ΔUL31 since the delay of α and β gene expression was extended in these cell 
types. Specifically, wild type levels of ICP4 and ICP8 expression were not 
reached until 12 hpi in cells infected with ΔUL31. Additionally, gC expression 
levels failed to reach wild type levels in Hep2 and HeLa cells by 18 hpi. 
     Infections of clone #7, RSC and Vero cells with ΔUL31 all resulted in a 
delay of gC expression at 12 hpi compared to wild type levels. However, gC 
levels in these cell types infected with the ΔUL31 mutant reached wild type 
levels by 18 hpi. Similar results were noted in cells infected with 50 PFU per 
cell of the UL31 deletion mutant (data not shown), suggesting that the 
differences was not consequential to a failure to infect a subset of the cells. 
    
 Discussion 
     Besides its well documented role in nuclear egress, the data presented 
here argue that pUL31 also plays a role in initiation of infection in some cell 
types. This is manifested by a delayed accumulation of early viral proteins in 
some cell types infected with a UL31 deletion virus. The defect in viral protein 
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accumulation correlates well with inefficient activation of NFκB and the 
downstream signaling molecule JNK. For example, at 18 hours post infection 
(hpi) IκBα levels in the non-permissive HeLa cells were down regulated to 7% 
of mock levels in the wild type HSV-1(F) infection (figure 4.2). This indicates a 
strong actvation of NFκB in these cells, whereas the IκBα level in HeLa cells 
infected with the UL31 deletion virus were at 78% of mock levels at 18 hpi 
(figure 4.2), indicating poor NFκB activation. Similarly, (activated) p-JNK levels 
in HeLa cells infected with the UL31 deletion virus infection was only 15% of p-
JNK levels in the repaired virus infection at 18 hpi (figure 4.2). Figure 5.2 
shows that at 18 hpi in HeLa cells ICP4, ICP8 and gC are all expressed at 
dimished levels compared to the repaired virus. Taken together, this suggests 
that activation of NFκB and JNK is important to ensure optimal viral gene 
expression. Alternatively, the failure to activate these signaling molecules may 
occur secondarily to inefficient initiation of infection. 
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CHAPTER VI 
Conclusions and Future Work 
 
     This dissertation addresses several components of HSV-1 infection and the 
presented data supports new roles for the host protein myosin Va in HSV-1 
secretion (chapter III) and the viral protein pUL31 in cell signaling and gene 
expression (chapters IV and V). These data and potential future work is 
discussed below. 
 
Myosin Va and HSV-1 Secretion 
     The goal of the work presented in chapter III was to determine the role of 
the actin motor myosin Va in HSV-1 secretion. While egress to the secondary 
envelopment site via microtubules has been described, little is known about 
how these vesicles transit the remaining distance to the plasma membrane for 
virion release. Based on the known roles for myosin Va in secretion of other 
vesicular cargo (130,173,174), it seemed possible that this motor may also be 
used for trans-Golgi network (TGN)-derived vesicles transporting HSV-1 
virions to the extracellular space. 
     In order to determine whether or not HSV-1 utilized myosin Va during 
secretion, HeLa and Vero cells transfected to express a dominant negative 
myosin Va (DN-myoVa) construct were infected with HSV-1. Titration of total 
infectivity (intracellular and secreted virions) and secreted infectivity (virions in 
the supernatant only) revealed that cells expressing DN-myoVa secreted 50-
75% less HSV-1 than control cells, while total infectivity produced by the DN-
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myoVa expressing cells was not reduced compared to control cells (chapter 
III). This suggests that myosin Va activity is required for secretion of HSV-1, 
but not for intracellular production of virions. 
     The implication of this finding is that myosin Va’s role appears to take place 
after secondary envelopment at the TGN and before these vesicles fuse with 
the plasma membrane to release the internalized virions. This fits with our 
proposed model (figure 6.1) that myosin Va is participating in a “hand-off” of 
virion-laden TGN vesicles from a kinesin motor in order to capture this cargo 
within the cortical actin and traffic the vesicle toward the plasma membrane. 
The observed decrease of viral glycoproteins B, M and D on the cell surface 
serves as an indication that the vesicles enriched with viral glycoproteins failed 
to fuse with the plasma membrane. Presumably, it is vesicles enriched with 
viral glycoproteins that are used by HSV-1 to egress from the cell (i.e. TGN-
derived vesicles) (158). Finally, data presented in chapter III demonstrating 
colocalization of TGN markers with the cytoplasmic aggregations of DN-
myoVa (tagged with red fluorescent protein) further support this model. 
     In order to further establish the model proposed above, future work 
includes directly correlating myosin Va activity with virion-laden vesicles in the 
cortical actin. HSV-1 labeled with two fluorescent tags, one on a capsid protein 
and another on an envelope protein, could be used to show whether or not 
myosin Va is necessary for virions to enter the cortical actin. Infecting cells 
expressing DN-myoVa with this dually-labeled virus and subsequently 
recording live cell dynamics by confocal or epifluorescence microscopy would 
reveal whether enveloped viruses (represented by pixels of the mixed  
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Figure 6.1 Model of HSV-1 Secretion via a Myosin Motor. Model depicting 
an HSV-1 capsid budding into a TGN-derived vesicle and subsequent 
transport along a microtubule filament via kinesin. Next, the vesicle is 
transferred to actin filaments and trafficked through cortical actin via myosin 
Va toward the plasma membrane for secretion.
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fluorescent colors) reached the periphery of the cell. The required reagents 
are currently available to the laboratory. 
     It would also be of interest to determine what effector protein(s) are used 
by myosin Va to bind its vesicular cargo (i.e. TGN-derived vesicles) in HSV-1 
infected cells. Effector proteins (including Rab GTPases) that interact with 
different exons of alternatively spliced myosin Va have already been described 
(24,64,127,165,173), and it would be of interest to know if myosin Va uses one 
or more of these proteins in epithelial cells, or if a different protein(s) is 
involved. Because both the brain and skin isoforms of DN-myoVa were 
effective at decreasing HSV-1 secretion, it is possible that in these (infected) 
cells the motor protein is associating with an unidentified effector that 
associates with a conserved region of myosin Va. Rab 11, which is known to 
associate with myosin Va in the brain, may also be a candidate since it is not 
know what region of the motor protein interacts with this GTPase. It is also 
formally possible that a viral protein is acting as a myosin Va effector. Data 
presented in chapter III indicated a robust activation of myosin Va at about 4 
hours post infection (as indicated by an altered conformation) that was 
dependent upon viral protein synthesis. Thus, viral proteins are influencing 
myosin Va dynamics and may direct the motor to specific cargo. 
     One possible experiment to elucidate myosin Va effector protein(s) during 
HSV-1 infection is immunoprecipitation (IP) with a myosin Va antibody. 
Proteins complexing with the antibody would be separated on a 
polyacrylamide gel by electrophoresis and stained with Coomassie blue to 
visualize proteins. Comparing IPs from infected and mock infected cells would 
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reveal potential viral effector proteins by the presence of additional bands from 
proteins complexing in the infected cell IP but not with mock infected cells. The 
proteins harvested from the IP could be identified by mass spectrometry or 
alternatively by immunoblot if the molecular weight match to a known myosin 
Va effector protein. The results could be confirmed by siRNA knock down 
and/or dominant negative mutants expressed in cells that are subsequently 
infected with HSV-1. Infection would be followed by collection and titration of 
secreted and total infectivity at 20 hours post infection, as was done with the 
DN-myoVa constructs (chapter III). 
 
pUL31: Role in Cell Signaling and Gene Expression in HSV-1 Infections 
     pUL31 has known roles in nucelocapsid egress as well as viral DNA 
(vDNA) replication and packaging (15,123,124,128). The data presented in 
chapters IV and V demonstrates additional roles for pUL31 in cell signaling and 
viral gene expression. Specifically, NFκB activation was reduced and/or 
delayed in multiple cell types infected with the UL31 deletion virus. This 
activation deficiency correlated with reduced/delayed activation of c-Jun-N-
terminal kinase (JNK) as well as delayed expression of viral proteins. 
Metabolic labeling experiments (chapter V) also demonstrated a reduced 
ability for host shut off compared to infections with wild type (F) or the repair 
virus. These defects were not due to inability to infect cells as ICP4 expression 
was noted in cell monolayers infected with the UL31 deletion virus at levels 
comparable to infections with the repair virus, albeit delayed. 
     The mechanism by which pUL31 mediates its effects on NFκB activation 
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and viral protein accumulation is unclear. pUL31 is not a component of 
extracellular virions (83). Proper virion assembly at later stages may be 
dependent on proper vDNA packaging and primary envelopment at the 
nuclear membrane (15,123). For example, defects in vDNA packaging might 
later compromise vDNA uncoating upon infection of new cells. It should be 
noted that these hypotheses assume complementation of the UL31 null mutant 
is incomplete in the pUL31 expressing cell line used to propagate the UL31 
virus, an assumption that is supported by the incomplete rescue of NFκB 
activation in the UL31 complementing cell line infected with the UL31 deletion 
virus (80).  
     Whatever the role of pUL31 to help initiate viral infection, eventually this 
block is relieved with time in RSC and Vero cells, though infection in some cell 
types such as Hep2 and HeLa are considerably more dependent on UL31. 
Previously presented data demonstrated that detectable levels of UL31 protein 
exist as early as 2 hpi (chapter IV). This presents the possibility that the 
nascent pUL31 accumulating at early times post infection is necessary for 
transcription and/or translation of viral genes. 
     Data presented in chapter IV showed that the defects of ΔUL31 cannot be 
rescued by expression of ICP27 in trans, suggesting that pUL31 performs 
different functions than this potent viral regulator. Importantly, the effect of 
pUL31 on viral protein accumulation can be distinguished from its interaction 
partner pUL34, because protein expression defects were not noted in cells 
infected with a UL34 deletion virus, consistent with previous reports (128).This, 
along with the fact that pUL31 exists solely in the nucleus in the absence of its 
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binding partner, argues against pUL31 acting on gene expression at the 
translational level. It follows logically that because pUL31 is located almost 
exclusively in the nucleoplasm in cells infected with the UL34 null virus (123), 
that the role pUL31 plays in augmenting viral infection is mediated not by viral 
budding from the inner nuclear membrane, but by other functions of pUL31 
performed in the nucleoplasm. Such roles might include transcriptional 
activation as well as an ancillary but important role in capsid assembly, DNA 
packaging as previously reported (15).  
     Incorrect DNA packaging or capsid assembly could conceivably confer 
early defects in subsequent infection by inefficiencies in entry or DNA 
uncoating at the nuclear pore (109). It is logical that incomplete blocks in these 
processes could be relieved by prolonged incubation, just as we see in cells 
infected with the UL31 deletion virus. 
     The most pressing future work for this project is the elucidation of a 
mechanism for pUL31’s role in gene activation. Because of pUL31’s strictly 
nuceloplasmic localization, its most likely role early in infection is related to 
transcription. In order to determine if transcription is down regulated during 
infection with the UL31-null virus, RNA isolation and subsequent analysis on 
DNA microarray chips would reveal which HSV-1 genes are actively 
transcribed. Comparing the UL31-null virus to RNA collected from the repaired 
would answer this question. Selected genes could be verified by real time 
PCR. Such a microarray is available to our laboratory through a collaborator. 
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